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ABSTRACT 
 
During the research and development stage of any drug candidate, there is a growing 
need to investigate the properties of existing enantiomers, if the drug possesses 
chirality. It is becoming increasingly more of a requirement to separate specific 
enantiomers in order to optimize the potency and reduce the toxicity of certain drugs. 
Consequently, there is a huge interest in devising analytical methods for the analysis 
and separation of enantiomers, thus leading to improved treatments of marketed 
pharmaceutical products. Cytarabine is a nucleoside analogue used as a 
chemotherapeutic agent for the treatment of acute lymphoblastic and myelogenous 
leukaemia. The aim of this study was to separate the enantiomers of anticancer 
reagent cytarabine by HPLC and investigate the effects of cytarabine enantiomers on 
specific cancer cell lines in order to identify if the enantiomers possess any specificity. 
The present study carried out the attempted separation of cytarabine enantiomers on 
three polysaccharide based chiral stationary phases namely; Chiralcel OD-H, Chiralcel 
OJ-H and Chiralpak AD-H using HPLC system. The effect of the varying compositions 
and the flow rates of mobile phases resulted in varying degrees of elution and 
separation. The conditions that afforded the best separation involved the use of the 
Chiralpak AD-H column  using mobile phase ratios consisting of n-hexane: 2-propanol 
(50:50, v/v), (60:40, v/v) (70:30, v/v) at a flow rate 1.5ml/min and n-hexane: 2-
propanol: diethylamine (50:50:0.2, v/v/v) and (60:40:0.2, v/v/v) at flow rate 1ml/min 
with excessive overlap. The application of the Chiralcel OJ-H column using mobile 
phase composition of n-hexane: ethanol: diethylamine (60:40:0.2 v/v/v) at a flow rate 
of 0.5ml/min also afforded partial separation with excessive overlap. The application 
of Chiralcel OD-H with varying compositions proved to be less effective than               
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Chiralcel OJ-H and Chiralpak AD-H columns. Partial separation was achieved with the 
employment of a gradient elution using combinations of n-hexane with 2-propanol on 
the Chiralpak AD-H. However, the gradient method proved not to be as effective as 
the isocratic system. The investigation highlighted the difficulties that exist in 
separating effectively specific chiral compounds. The fact that there was variation in 
peak shape, even after analysing the same sample repeatedly was a significant 
challenge which clearly hampered resolving the peaks. 
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1. INTRODUCTION  
1.1 Chirality  
 
Structural differences create a significant impact on the way molecules interact with 
the surrounding and other compounds. Even though the molecule can be identical in a 
number of ways for example molecular formula and connectivity, they can differ on 
their spatial properties that have a profound effect on the way they react with other 
compounds. Chirality is formally defined as the geometric property of a rigid object 
which is not superimposable with its mirror image and the existence of left and right 
position. It is applied to molecules, conformations as well as macroscopic objects such 
as crystals (Francotte and Lindner, 2006; Brown et al., 2009). Chirality is an essential 
and ubiquitous property of living nature since many important molecules in nature are 
chiral including proteins, nucleic acids, enzymes, carbohydrates, alkaloids, and also all 
resulting macromolecules like deoxyribonucleic acid (DNA), ribonucleic acid (RNA) 
(Reddy and Mehvar, 2004). Thus, the phenomenon of chirality plays a key role in life of 
plants, animals, pharmaceutical, agricultural industry. The most fundamental 
development occurred when a tetrahedral carbon atom was proposed as a basis for 
molecular chirality by Dutch and French chemists Jacobus Henricus Van’t Hoff and 
Joseph Achille LeBeli (Francotte and Lindner, 2006).  When two chemically identical 
molecular species differ from each other as non-superimposable mirror images they 
are called as enantiomers for example S and R lactic acid (Beesley and Scott, 1998)   
(Fig 1.1).  
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COOH
H3C OH
H
COOH
CH3HO
H
S (+) lactic acid                             R (-) lactic acid  
Figure1.1: The chemical structure of S and R lactic acid as enantiomers. (The chemical 
structure was drawn using the chemdraw ultra 12.0 software). 
 
The simplest example of chirality is a sp3-hybridized tetrahedral carbon atom to which 
four different substituents are attached, this molecule does not have a plane of 
symmetry and is called chiral for example the anti-depressant drug fluoxetine which 
has one chiral carbon and therefore exists as a pair of isomers called enantiomers     
(Fig 1.2), the S-enantiomers of which possesses a higher pharmacological activity 
(Shamsipur et al., 2007). 
 
F
F
F
O
HN
R-fluoxetine
F
F
F
O
HN
S-fluoxetine
 
Figure 1.2:  R and S enantiomers of fluoxetine with one chiral carbon and four different groups 
attached to it.  
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Figure 1.3: Some landmarks in chirality (Adapted from Burrows et al., 2009). 
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1.2 Important terms of chiral chemistry 
1.2.1 Achiral  
If an object and its mirror image are superimposable then the original object is termed 
as achiral. An object can be called achiral when it has one or more elements of 
symmetry such as plane of symmetry and centre of symmetry for example cyclobutane 
(Fig 1.4), it has a centre of symmetry so is identical to its mirror image and is achiral 
(Brown et al., 2009).  
C
C C
C
H
H
H
H H
H
H
H
 
Figure 1.4: The chemical structure of achiral cyclobutane.  
 
1.2.2 Prochiral 
 
A molecule is considered prochiral if it can be converted into a chiral or achiral molecule 
in a single chemical step for example 2-butanone which gives 2-butanol on reduction 
(Fig 1.5) (McMurry and Begley, 2005). 
O
CH3C CH2 CH3
OH
CH3C CH2 CH3
H
   2-Butanone                                                         2-Butanol     
    (prochiral)                                                             (chiral)  
Figure 1.5: The chemical structure of prochiral 2-butanone which gets converted to 2-butanol, 
a chiral compound on reduction.  
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1.2.3 Isomers  
These are compounds with same molecular formulae but different structural 
arrangements. The outcome of isomerism yields practically various compounds which 
possesses different properties from each other (Turker, 2002). The types of isomers 
are constitutional, stereoisomers, configurational isomers, conformational isomers, 
geometric isomers, optical isomers, diastereomers and enantiomers. 
1.2.3.1 Diastereomers  
The compounds with one chiral centre exist as enantiomeric pair, whereas compounds 
with two or more chiral centres can exist as diastereomers or diastereoisomers                                           
(Metzler and Metzler, 2003). They are stereoisomers with a different configuration 
and are not related as mirror images having different chemical and physical properties. 
Molecules possessing more than one chiral centre also exhibit diastereomerism 
because inverting one or more (but not all) of the centres leads to structures which do 
not have a mirror image relationship with the original. Inversion of a single chiral 
centre gives an epimer of the original structure. Inversion of all stereogenic centres 
gives the enantiomer. A molecule possessing    n  chiral centres has a maximum of 2n 
stereoisomers, 2n -1 pairs of enantiomers and    n  epimers (Burrows et al., 2009). 
Molecular symmetry within the molecule may result in a reduction of the numbers of 
different isomers due to internal compensation.  
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Figure 1.6: Relationship between isomers and their types (Adapted from 
http://www.chem.ucalgary.ca/courses). 
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1.2.4 Anomers  
A pair of diastereomeric aldoses that differ only in configuration about the first chiral 
carbon are called anomers e.g. pair of aldoses α D(+) glucose and β D(+) glucose              
(Fig 1.7). They differ in configuration of H atom and the OH group about its first carbon 
atom and have the same configuration about the remaining carbon atoms           
(Beesley and Scott, 1998).  
OH
OH
OH
HO
O
OH
OH
OH
OH
HO
O
OH
D (+) glucose                                      D (+) glucose  
Figure 1.7: The chemical structure of α D (+) glucose and β D (+) glucose.  
 
1.2.5 Epimers 
They are diastereomers that differ in configuration at only one position or stereogenic 
centre (Smith et al., 2007). Pair of diastereomeric aldoses that differ only in 
configuration about second chiral carbon are known as epimers                                  
(Beesly and Scott, 1998).  The structure of aldoses D glucose and D galactose only 
differ in configuration of the H atom and OH group in the second carbon atom but 
have the same configuration in the remaining carbon atoms (Fig 1.8).  When a 
molecule contains more than one chiral centre and configurational inversion takes 
place at one chiral centre only, which is reversible, then the product formed is not an 
enantiomer of original compound but it is a diastereomer or more specifically an 
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epimer and this process is called as epimerisation (Nasipori, 1994). Thus the epimeric 
form of a chiral form can be converted to another using an enzymatic action and this is 
known as epimerisation. 
          
CHO
OHH
HHO
OHH
OHH
CH2OH
CHO
OHH
HHO
HHO
OHH
CH2OH
       D- Glucose                                          D-Galactose  
Figure 1.8: The chemical structure of D-glucose and D-galactose as epimers which differ in 
configuration of the H atom and OH group in the second carbon atom.  
 
1.2.6 Meso compounds 
Some compounds are superimposable mirror images of each other; compounds 
possessing such structures are not chiral. Their molecules have chiral centres but are 
not themselves chiral and are termed meso compounds. Chiral compounds have the 
property to rotate the plane of polarisation of plane polarised light but a meso 
compound is unable to do so, since they are not chiral they are not (-) levorotatory or 
(+) dextrorotatory (Smart and Gagan, 2002). When there are   n  chiral centres, the 
isomeric configuration will be 2n for example, ephedrine, pseudoephedrine. If the 
groups around the chiral centres are the same then the number of stereoisomers is 
less than 2n. Therefore, when n=2 there are only three stereoisomers and not four for 
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example tartaric acid (Fig 1.9). These stereochemical principles apply to both acyclic 
and cyclic compounds (Dewick, 2006). 
COOH
OHH
OHH
COOH
meso tartaric acid  
Figure 1.9: The chemical structure of meso tartaric acid.  
 
 1.2.7 Optical purity (Enantiomeric excess) 
 
While dealing with a pair of enantiomers it is very important to have a means of 
describing the composition of that mixture and the degree to which one enantiomer is 
in excess. The composition of mixture of enantiomers can be described by their optical 
purity.  The optical purity is the specific rotation of a mixture of enantiomers divided 
by specific rotation of enantiomerically pure substance when they are in same 
concentration. Another way is to describe the composition of a mixture of 
enantiomers by its enantiomeric excess (ee). ee can be defined as the difference in the 
number of moles of each enantiomer in a mixture compared to the number of moles 
of both enantiomers (Brown et al., 2009). Numerically optical purity and ee are the 
same. ee = % (R) - % (S) where ee = enantiomeric excess, R and S enantiomers                          
% = percentage of enantiomers for example, if a mixture has 60% of R enantiomer and 
40 % of S enantiomer, then the ee for R enantiomer will be 20%.  
 
35 
 
1.2.8 Nomenclature of enantiomers 
 
1.2.8.1 Optical activity (+ or -) 
Numerous substances have the property to rotate through a certain angle the plane of 
polarisation or plane of vibration of a polarised light which is passed through them, 
some of them rotate it to the left and others to right. Such substances can be called 
optically active or circular polarising and this phenomenon is called as optical activity 
(Burrows et al., 2009). The enantiomer rotating the plane-polarized light in clockwise 
direction is called (+) enantiomer and the other enantiomer which rotates the plane-
polarized light in anticlockwise direction is called (-) enantiomer (Burrows et al., 2009). 
1.2.8.2 Absolute configuration (dextrorotatory and levorotatory) 
The D/L labeling is unrelated to (+)/(−); it does not indicate which enantiomer is 
dextrorotatory and which is levorotatory. Rather, it says that the compound's 
stereochemistry is related to that of the dextrorotatory or levorotatory enantiomer of 
glyceraldehydes. If the OH group of the second carbon is on the right hand side than 
the enatiomer is named D and if the OH group of the second carbon is on the left hand 
side than the enatiomer is named as L (Burrows et al., 2009). 
1.2.8.3 R and S configuration 
Cahn, Ingold and Prelog devised a system based on assigning sequence rules based on 
decreasing atomic number for projection formulas that allows absolute configuration  
assignments of R (rectus, Latin for right) and S (sinister Latin for left). This is the 
internationally accepted nomenclature for chiral molecules. The Cahn-Ingold-Prelog 
(CIP) rule is used for sp3-hybridised carbon. The four groups are sorted on the basis of 
increasing mass of the atom attached to the asymmetric chiral centre and so on. If two 
atoms are identical e.g. 2-butanol, the next higher mass atom one bond away is 
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considered and so on. Next will be the molecule held by the lightest mass. Hence the 
three other substituents arranged in decreasing mass order define R-enantiomer. The 
mirror image of the R-2-Butanol is the S enantiomer (Fig 1.10). These rules can be used 
to find the absolute configuration of any chiral compound in nature                          
(Crowe et al., 2006). The second way to designate these stereoisomers is to assign the 
configuration as R or S, based on stereostructure of enantiomers with one chiral 
centre. On the basis of their three dimensional structures R and S are relative 
configurations and it is not possible to predict if the R enantiomer will be 
dextrorotatory or levorotatory (Hoffman, 2004).  
H3C
H
CH2CH3
OH
1
4
3
2 H3CH2C
H
CH3
OH
1
3
2
4
            R- (2- butanol)                                                            S- (2-butanol)  
 
Figure 1.10: R, S nomenclature for enantiomers of 2-butanol based on the increasing mass of 
the atom attached to the asymmetric chiral centre. 
 
1.2.9 Racemate 
 
Mixtures of substances that have dissymmetric molecular structures and are mirror 
images of each other in equimolar proportions are known as a racemic mixture. Each 
enantiomer rotates the plane of polarisation of plane polarised light in an angle but 
the racemic mixture is optically inactive due to the rotary effect of each enantiomer 
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cancels that of the other enantiomer, hence it cannot exhibit optical activity. This 
name is derived from racemic acid. For example racemic tartaric acid which was 
isolated from potassium tartrate in 1769 by the Swedish chemist Carl Wilhelm Scheele 
(Fig 1.11) (Burrows et al., 2009). Naturally occurring tartaric acid is chiral and it is used 
in the synthesis of other chiral materials. The natural form of tartaric acid is 
levotartaric acid (-)-tartaric acid 2, 3-dihydroxysuccinic acid. Pasteur was the first to 
produce a pure sample of levotartaric acid.  The other enantiomer form is 
dextrotartaric or (+) tartaric acid. The mixture of these two levo and dextro forms is 
called racemic tartaric acid.  
COOH
HHO
OHH
COOH
COOH
OHH
HHO
COOH
Levotartaric acid                                   Dextrotartaric acid  
Figure 1.11:   The Chemical structure of levotartaric acid and dextrotartaric acid, these when 
mixed together result in racemic tartaric acid.  
 
1.2.10 Racemisation 
When many optically active compounds are subjected to heat, in the presence of 
alkalis or acids they can go through optical inversion and an optically inactive 
compound is produced which contains equal quantities of two optical antipodes. The 
product is called a racemic product and this process is known as racemisation. It is a 
spontaneous post translation process (McCudden and Kraus, 2006). 
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1.2.11 Resolution 
Enantiomers have identical physical properties and can be distinguished only in a 
chiral environment. The interaction between a mixture of enantiomers with single 
enantiomers of chiral compounds result in a mixture of diastereomers (Fig 1.12). Since 
diastereomers have different physical properties they can be separated. Once 
separation takes place the individual isomers can be obtained (Hoffman, 2004). Hence 
chiral resolution in stereochemistry is the separation of racemates into its 
enantiomers. It is also known as optical resolution or mechanical resolution. 
 
Figure 1.12: The formation of diastereomers by the interaction of mixture of enantiomers with 
single enantiomers (Adapted from Hoffman, 2004). 
 
1.3 Polarimeter  
The polarimeter measures the rotation of polarized light as it passes through an 
optically active fluid. It consists of a monochromatic light source, a polarizing filter, an 
analyzing filter and a sample tube (Fig 1.13). When the filled solvent tube is placed in 
the polarimeter, the analyzing filter must be adjusted so the field of view is dark. This 
position of the analyzing field is considered as 0o. When the solution of optically 
compound is placed in the sample tube, some light passes through the filter. The 
optically active compound rotates the plane of polarized light from polarizing filter so 
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that it is no longer at an angle of 90o to analyzing filter. The analyzing filter is then 
rotated to restore darkness to the field. If the analyzing filter is turned to right 
(clockwise) then the compound is dextrorotatory and if it is turned to the left (counter 
clockwise) then it is called levorotatory (Brown et al., 2009). 
 
Figure1.13:  Schematic diagram of a polarimeter. Showing the sample tube filled with the 
sample containing an optically active compound. With the analysing field turned clockwise to 
α degree to restore the dark field to the observer (Adapted from Brown et al., 2009). 
  
The angle through which the plane polarized light is rotated is called the optical 
rotation and is given symbol α. It is proportional to the number of optically active 
molecules present in the beam of polarized light so it depends on the concentration (c) 
of optically active compound and the path length (l). The standard for comparison of 
all molecules is called specific rotation     
  
  (where D is line of sodium lamp (589nm) 
and the superscript indicated the temperature in degrees Celsius). 
 
    
  = 
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Figure1.14:  Optical processes in the polarimeter (Adapted from Kott et al., 2006). 
 
1.4 Importance of chirality 
Except for inorganic salts and a few low molecular weight organic compounds, most of 
the molecules in living systems possess chirality (Brown et al., 2009). Many of the most 
widely prescribed drugs today are chiral molecules. It is important to promote 
separation of enantiomers and their analysis for the requirement of stereo-
pharmacokinetic studies and stereospecific drug assays (Burke and Henderson, 2002). 
Metabolic behaviour, bioavailability, distribution and excretion behaviour are crucial 
determinants of drug action.  Very often one of the two enantiomers represents a 
more active isomer for a given action (eutomer), while the other enantiomer 
(distomer) may be active in a different way, leading to side effects, or acting as 
antagonist or displaying toxicity  (Aboul-Enein and Wainer, 1997; Caldwell, 1995). US 
FDA (food and drug administration), European Committee for Proprietary Medicinal 
Products and other regulatory agencies have restricted the use racemic drugs. They 
have defined stricter requirements to patent new racemic drugs demanding full 
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documentation of pharmacological and pharmacokinetic profiles of individual 
enantiomers as well as their combinations (Ali et al., 2009). Hence, some of the 
pharmaceutical companies are manufacturing pure enantiomeric drugs using 
enantiomeric separation techniques. Despite the fact that these differences of chiral 
enantiomers have been known for more than two decades, however, during the past 
decades tremendous advances have arisen in the development of enantiomerically 
pure compounds with the help of powerful analytical and preparative separation 
techniques (Maier et al., 2001). The separation of optical isomers requires an 
asymmetric or chiral environment that allows diastereomeric interactions (Torok et al., 
2005). Chiral chromatography is an important analytical tool for the determination and 
separation of inactive enantiomers in enantiomerically pure drugs (Nageswara et al., 
2006b).  It was only during start of this decade that the commercialisation of 
enantiomerically pure drugs was suggested as a desirable challenge with a number of 
practical limitations (Maier et al., 2001). The drug has more complex pharmacological 
and analytical situation with the increasing number of chiral centres.  
1.5 Toxicology of chiral drugs 
The action of drugs is a result of pharmacological and pharmacokinetic processes by 
which it enters, interacts and leaves the body (Maier et al., 2001). Large 
pharmacokinetic and pharmacodynamic differences are frequently observed between 
enantiomers. Hence enantiomers may result in stereoselective toxicity. The 
toxicological properties in a pair of enantiomers can be identical or entirely different. 
They can reside in the pharmacologically inactive enantiomer or the active one   
(Drayer, 1986). For example Dopa or dihydroxy-3,4 phenylalanine was used under 
racemic form d,l-dopa but due to the toxicity of d-isomer only levorotatory form            
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(L-dopa) is used in therapeutics. Another common example of a pair of enantiomers 
that proved to have devastating effects is Thalidomide (Thalomid TM) used to treat 
epilepsy (Melchert and List, 2007). During the last century, the thalidomide incident 
dramatically drew attention towards the importance of chiral activity and the need to 
use enantiomerically pure drug forms (Bosch et al., 2008).  Due to the lack of sufficient 
efficacy as an anti-epileptic it was used as an antiemetic during pregnancy and a sleep 
aid (Randall, 1990). It exhibited irreversible neurotoxicity and teratological effects 
which led to the deformation of babies born. It was found that these effects were 
caused by the S-enantiomer and that the R-enantiomer had the required therapeutic 
activity (Fig 1.15). Prior to the introduction of thalidomide approved drugs could be 
racemic, but experience from that drug has now set new standards for purity assays       
(Webster and Kott, 2010). However, many chiral drugs are still marketed under mixed 
form because either their chiral separation is difficult or their pharmacological and 
toxical effects reside in the same enantiomer or due to high cost productions 
(Waldeck, 2003). 
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Figure 1.15: The structure of S and R enantiomer of thalidomide. The S-enantiomer had 
teratological effects while the R enantiomer had the required therapeutic activity. 
43 
 
1.6 Mechanism of biological activity 
Biological processes that are mediated by or involve chiral molecules like enzymatically 
catalyzed biotransformation or receptor-ligand interactions can be stereoselective and 
this leads to implications of biologically active compounds interacting with them 
(Maier et al., 2001). Certainly, biological systems can recognize the two enantiomers 
as different substances and therefore elicit different responses. The reason for the 
chiral recognition by drug receptors is a three-point interaction of the drug with the 
receptor site proposed by Easson and Stedman (Burke and Henderson, 2002)                    
(Fig 1.16). The active enantiomer drug labelled A, B and C interacts with the 
corresponding binding sites (a, b, and c) while the inactive enantiomer cannot bind in 
the same way, consequently there is not an active response. 
 
Figure 1.16: The three point interaction of the drug with its receptor site. The three 
substituent A, B, C of active enantiomer (left) can interact with the three binding sites by 
forming Aa, Bb, Cc whereas the inactive enantiomer cannot.  (Adapted from McConalthy et al., 
2003). 
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1.7 Cytarabine 
Recently, nucleoside analogues have become the prime focus of many scientists for 
the treatment of cancer and various dreadful viral diseases. This class of drugs share 
the same pharmacodynamics and metabolism pathway with their purines and 
pyrimidines (Heidelberger et al., 1983). The drugs when injected get incorporated into 
one of the DNA strands during DNA replication or DNA repair synthesis resulting in 
stalled DNA replication and chain termination. The cell triggers the activation of 
various checkpoint pathways which causes the arrest of the cell cycle during the S 
phase and also signals for DNA repair (Glick and Pasternak, 2007). If the survival 
mechanism fails to repair the damage DNA, the cell triggers another signalling 
pathway that initiate apoptotic processes (Cheson et al., 1997).  These nucleoside 
analogue shows diversity in their clinical activities in spite of sharing the same 
structural features and metabolic pathways. This study involves enantioseparation of a 
chiral drug by the name of cytarabine.  
Nucleosides, which are frequently altered in the carbohydrate moiety, became the 
focus for the development of nucleic acid analogs. Most efforts were directed at the 
constituents and their configuration about the 2' - carbon, as this is a site at which 
DNA metabolizing enzymes are quite discriminating. One of the first pyrimidine 
nucleoside analogs to be developed containing alteration in carbohydrate moiety was 
cytarabine, an analog of deoxycytidine (ara-C, 1-β-D-Arabinofuranosylcytosine, 
Cytosar-U) (Sun et al., 2008). Cytarabine is an anticancer chemotherapeutic drug, and 
is among the most effective anticancer agent used for the treatment of both chronic 
and acute myeloblastic leukaemia (Stornio et al., 1999). 
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Figure 1.17: The chemical structure of cytarabine. 
Synthesis of the lagging DNA strand at the replication fork occurs discontinuously and 
requires unwinding of the parental DNA strands, de novo synthesis of an RNA primer 
and elongation of the nascent DNA chain. Completion of the replication process 
requires excision of the RNA primer by ribonuclease H (RNase H) and ligation of the 
DNA chains by DNA ligase. Okazaki fragments occur as intermediates during 
replication of the lagging strand and contain the RNA primer and the nascently 
synthesized DNA associated with the lagging DNA strand through complementary base 
pairing (Russell, 2006) (Fig 1.18). 
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Figure 1.18: Depiction of Okazaki fragments that have occurred as intermediates during 
replication of DNA. Lagging strand synthesis took place in discontinuous manner. New DNA 
segments hydrogen bonded to the template strand have RNA primers at their 5ʹ ends. RNA 
primers are removed by RNAse, DNA polymerase filling the resulting gaps and DNA ligase joins 
the adjacent gaps (Adapted from Gmeiner et al., 1998). 
 
One of the principal distinguishing characteristics between normal and malignant cells 
is the occurrence of nuclear DNA replication along with cell division (malignant cells 
lack G0 phase). Cytarabine is cytotoxic to a variety of mammalian cells in culture. The 
exact mechanism of action of cytarabine has not been fully known, however it acts 
through DNA synthesis inhibition.  It acts by blocking the utilisation of deoxycytidine 
triphosphate, thereby killing cells that are undergoing DNA synthesis                          
(Yamauchi and Ueda, 2005). Its mechanism of action includes the transportation of 
Arabinosylcytosine (ara-C) into leukemic cells by membrane transporters such as 
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human equilibrative nucleoside transporter 1 (hENT1) (Wiley et al., 1982). Upon 
entering the cell, an enzyme called deoxycitidine kinase (dCK) phosphorylates ara-C, 
and converts it into ara-C monophosphate. Ara-C monophosphate is then 
phosphorylated to ara-C diphosphate by deoxycytidine monophosphate kinase, and 
ultimately nucleoside diphosphate kinase phosphorylates it to ara-C triphosphate  
(ara-CTP) which is an active metabolite of ara-C (Garcia-Carbonero et al., 1996). Ara-C 
then incorporates into DNA strand in place of deoxycytidine triphosphate dCTP during 
the S-phase of the cell cycle, which results in the inhibition of DNA synthesis. 
Therefore the cytotoxicity property of cytarabine results from inhibition of DNA 
polymerase α and the incorporation of ara-CTP in place of dCTP                                   
(Yamauchi et al., 2009).  
Intrinsic and extrinsic pathway leading to cell death mediated by cytarabine  
Intrinsic pathway to cell death: 
The intrinsic pathway of apoptosis triggered by DNA damage caused by nucleoside 
analogs results in mitochondrial-dependent activation of caspases, which executes the 
death program. Caspase activation causes the release of the cytochrome c from the 
mitochondria. Released cytochrome c triggers the formation of death complex 
apoptosome consisting of Apoptotic protease activating factor-1 (Apaf-1) and 
procaspase-9. Procaspase-9 activates the effectors caspase-3 and caspase-7 that leads 
to the characteristic apoptotic phenotype (Gunji et al., 1991).  
Ara-C mediated c-Jun N-terminal kinases (JNK) signalling directly participate in the 
intrinsic pathway leading to apoptosis by translocating to the mitochondria and 
interacting with the death proteins such as B-cell lymphoma 2 (Bcl) and second 
mitochondria-derived activator of caspases (SMAC).  JNK regulates the 
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phosphorylation of p53 protein which regulates the mitochondrial apoptosome. The 
transcription factor p53 in turn causes induction of many pro-apoptotic genes such as 
Bcl-2–associated X protein (BAX), Bcl-2 Homology Domain 3 (BH3) and NOXA (Latin for 
damage) Noxa protein is also known as phorbol-12-myristate-13-acetate-induced 
protein 1(PMAIP1) (Fig 1.19) (Sampath et al., 2003).  
Extrinsic pathway to cell death: 
The extrinsic pathway utilised by the nucleoside analogue to induce apoptosis require 
the participation of death receptors such as Fas receptor (FasR) that senses the death 
signal and translocated to the mitochondria. Ara-C once injected, causes upregulation 
of Fas and TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 without the 
requirement of p53 protein. Once induced, the death receptor causes activation of 
caspase-8 and caspase-3 that executes the cell death program (Sampath et al., 2003) 
(Fig 1.19).  
 
Figure 1.19: The nucleoside analogue induced extrinsic and intrinsic pathway cascades leading 
to cell death. (Adapted from Sampath et al., 2003). 
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1.8 Enantiomer separation techniques 
Chiral drugs require special analytical techniques that can differentiate between the 
various enantiomers at different levels (Wozniak et al., 1991). There are different 
analytical techniques available depending on the type of analysis to be performed    
(Fig 1.20).  
 
Figure 1.20: Some common enantiomer separation methods. 
 
The conventional method of separating the optical isomers of racemic compounds 
involves the treatment of isomers with a chiral reagent to produce a pair of 
diastereomers (Sorrel, 2006). These diastereomeric intermediates can then be 
separated by differential crystallization, hydrolysis and purification                                  
(Lorenz et al., 2007). Enzymatic Kinetic resolution uses enzymes like lipase, only one 
enantiomer of a chiral reactant fit to the active site properly and is able to undergo the 
reaction while the second enantiomer is left unreacted and in enantiomerically pure 
form. Enzymatic catalyzed kinetic resolution is the most common way to prepare 
enantiomerically pure compounds on an industrial scale (Martin-Matute and Backvall, 
2007). Other techniques include differential scanning calorimetry (DSC), spectroscopy 
and chromatography. Infrared spectroscopy and differential scanning calorimetry can 
only discriminate between mixtures and individual enantiomers. The differential 
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scanning calorimetry uses the melting range of the analyte to distinguish between 
mixture of enantiomers and single enantiomer (Jacques et al., 1981). Spectroscopic 
methods include infrared spectroscopy, nuclear magnetic resonance and optical 
rotation. Spectroscopic methods cannot trace low levels of enantiomeric impurities. It 
is furthermore difficult to differentiate between various isomers of compounds with 
one or more chiral centre. With optical rotation there is a requirement of a pure 
standard of one of the enantiomers. Chromatographic techniques are the most 
popular and most commonly used techniques for enantioselective analysis. It is a 
separation technique whereby the components of a mixture may be separated by 
allowing a sample (analyte) to be transported through a packed body of materials 
(stationary phase) by a fluid mobile phase (Heftmann, 2004). Chromatographic 
techniques can be divided into gas chromatography (GC), thin layer chromatography 
(TLC), supercritical fluid chromatography (SFC), capillary electrophoresis and high 
performance liquid chromatography (HPLC). In chiral liquid chromatography the most 
common detectors used are the ultra violet (UV), fluorescence and electrochemical 
detectors.  Polarimetric detectors can be used in combination with chiral and non 
chiral liquid chromatography (Lloyd and Goodall, 1989; Salvadori et al., 1991). The 
main advantage about chiral liquid chromatography is that it can be used for 
qualitative and quantitative work in combination with the polarimeter.  It also 
provides reliable result accuracy compared to other techniques. These techniques 
except for infrared spectroscopy and differential scanning calorimetry can discriminate 
between individual enantiomers (+) from (-) and (-) or (+) from (+/-) and hence can be 
used for qualitative and quantitative analysis. This research utilizes HPLC for the 
separation anticancer reagent cytarabine. 
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1.9 High performance liquid chromatography (HPLC) 
High performance liquid chromatography has been the fastest developing 
chromatographic technique over the past two decades (Fig 1.21). HPLC has very likely 
impacted the development of every drug candidate within the pharmaceutical 
industry. It is generally one of the most direct and efficient methods for the 
determination of enantiomeric purity (Karcher et al., 2005). The method is highly 
sensitive and accurate for quantitative determinations and is used extensively for 
substances that are of major interest to science, food industry, health care and 
forensics. HPLC can separate proteins, amino acids, hydrocarbons, pesticides, 
antibiotics, nucleic acids, steroids, metal and non metal organic substances 
(Krupadanam et al., 2001). It is comparatively fast as it forces the solvent to pass 
through the column under high pressure. Also it is highly automated and very 
sensitive. HPLC is more widely used compared to other chromatographic techniques, 
since the interaction between solute and chromatographic system takes place to a 
larger degree. This is due to the interactions favoured by lower operating 
temperatures. HPLC uses a broad choice of mobile phases and stationary phases. 
Furthermore, samples can be recovered without being destroyed. Its major advantage 
includes the reuse of columns.  
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Figure 1.21: High Performance Liquid Chromatography system. (Adapted from 
http://www.jascofrance.fr/pdf/hplc.pdf). 
 
1.9.1 HPLC components  
A typical HPLC system includes the following components: 
Mobile phase – it is the liquid flowing through the system which is chosen for the best 
separation of the components in an unknown mixture. This is chosen on the basis of 
polarity of the sample and the stationary phase. 
Solvent reservoir – it is used for the storage of sufficient quantities of HPLC solvent for 
continuous operation of the HPLC system. It can include a degassing system and filters 
to keep the solvent isolated from the influence of environment.  
Column – Based on the type of separation required an appropriate column is chosen. 
The column actually produces the separation of an analyte in the mixture. Different 
columns can produce different results due to varying composition of the packing 
material. 
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Column oven – usually a laboratory has an adequate climate control but temperature 
fluctuations can occur due to ventilation, heating or air conditioning. It is known that 
the column temperature plays an important role in HPLC retention and selectivity 
(Synder et al., 2009).  
Pump – continuous, constant and pulse free flow of the mobile phase through the 
system is provided by the pump. Pumps are designed for either constant flow 
operation or constant pressure. As long as the resistance (column) remains constant, a 
constant pressure will produce a constant flow. 
Injector - The analyte or analyte mixture is introduced into the stream of mobile phase 
before it enters the column through the injector. The maximum injection volume 
depends on the sample loop based on the injection valve.  
 
Figure 1.22: Diagram of a typical injector. (Adapted from http://www.hitachi-
hitec.com/global/science/lc/img/lc_basic/lc_basic_3_3_e.gif). 
 
For quantitative analysis it is always important to use a small loop and an overflow 
injection of the sample, so that the injector is fully saturated with the sample                
(Hanai, 1999). 
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Detector – this device allows continuous registration of specific physical (sometimes 
chemical) properties of column effluent. It is used for monitoring and continuous 
registration of UV absorbance over a span of wavelengths or a selected wavelength. 
Appearance of analyte in the detector causes the absorbance to change. A positive 
signal is obtained when the analyte absorbs greater than the mobile phase. They are 
widely used due to their relative low susceptibility to flow rate fluctuations. 
Data acquisition and control system - these are computer based systems that control 
all parameters of HPLC instruments e.g. temperature, injection sequence. In addition, 
acquires data from the detectors and monitors system performance. 
 
1.9.2 Working of HPLC 
The technique involves separation of the components in a mixture pushed through the 
column usually at a constant flow rate using a liquid mobile phase. The solvent (mobile 
phase) is run through the high pressure pump which generates and measures the flow 
rate of the mobile phase in millilitres per minute (ml/min). The sample to be analysed 
is introduced in the injector from where it is introduced in the mobile phase flowing 
through the column consisting of chromatographic packing material. From the column 
the flow is directed to the detector. The components are then analyzed by the 
detector from where the chromatographic image is produced in the computer. The 
chromatogram produced displays the retention time and the peak area of the 
expected compound. The retention time is a characteristic of the sample for a 
particular set of conditions and helps in identification of the compound. Different 
compounds have different retention times based on the nature of the stationary 
phase, nature of mobile phase and the flow rate of mobile phase. The peak area of the 
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compound indicates its concentration (Lindsay and Barnes, 1992; Kazakevich and 
Lobrutto, 2007). 
 
1.9.3 Direct and indirect mode of separation 
The separation of enantiomers by chiral chromatography is divided into two modes 
indirect mode and direct mode. Both direct and indirect separation methods provide 
different options to achieve separation of enantiomers and their quantification. 
Methods are chosen on the basis of chemical structure of the solute. Indirect mode 
uses an off column conversion of the original enantiomers with an optically pure 
derivatizing agent by chemical reaction. It involves the formation of diastereomers 
before the separation. Diastereomers have different physical and chemical properties 
unlike enantiomers that have same physical and different chemical properties, thus 
enabling their separation in a non chiral environment. Indirect method requires a 
functional group in the molecule at which the derivatization can take place. The 
functional group must be located near the chiral centre. One of the advantages of the 
indirect mode of separation is that it can be performed on a traditional column such as 
C18. Its disadvantages are that the derivatization reaction requires lot of time and can 
result in unwanted products or racemisation. Furthermore optically pure derivatizing 
agents may not be available. Some derivatizing agents for indirect separation are 
amino acids, alcohols, carboxylic acid and amines. 
The direct mode uses a chiral stationary phase for the chromatographic separation of 
enantiomers. In the chromatographic system it requires the creation of chiral 
environment. The direct mode involves different diastereomeric molecular association 
between the chiral non racemic stationary phase and the chiral analyte. For 
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enantiomers to be separated directly over chiral stationary phases (CSP), they must 
form short lived diastereomeric molecular complexes of non identical stability by 
interacting rapidly and reversibly (Francotte and Lindner, 2006). The present study 
involves the use of the direct mode of separation of the chiral anticancer reagent 
cytarabine. 
 
1.10 Chiral stationary phases (CSP) 
One of the most important and challenging aspects of chiral chromatography is to 
choose a good stationary phase. In chiral liquid chromatography, the separation of 
enantiomers provides a number of possibilities in experimental design and there are 
many stationary phases that can be used in combination with different mobile phase 
system to achieve resolution (Lammerhofer, 2010). Generally in chiral liquid 
chromatography, the column consists of small solid particles called sorbent and its 
purpose is to exhibit different affinities towards the two enantiomers in the column, 
and hence a difference is created between their retention times large enough to 
separate enantiomers. When any chiral compound passes through the chiral column it 
will be partitioned between the mobile phase and the sorbent used for elution and the 
affinity of each enantiomer will determine the time spent in the column during 
separation. While choosing a chiral stationary phase many important factors should be 
considered such as solubility of samples in mobile phase, structural characteristics of 
the analyte, cost of the column, mobile phase, waste treatment, analysis time, 
transferability or method robustness (Ahuja and Rasmussen, 2007). 
The direct separation method used to separate chiral compounds using HPLC is 
extensively used in the pharmaceutical industry and in biochemistry                           
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(Tachibana and Ohnishi, 2001). A large number of chiral stationary phases have been 
developed since the last 25 years such as ligand exchange, brush type, cyclodextrin, 
protein and polysaccharide types CSP (Lammerhofer, 2010). 
 
1.10.1 Brush-type columns 
Silica can be derivatized on almost any functional group; the resulting monomer 
structures are called brushes. It is assumed that silica based, brush-type stationary 
phases are characterized by a monomolecular organic layer on the silica surface, 
resulting from the attachment of a single chiral molecule to the silanol groups 
(Gasparrini et al., 2001). It was invented by William H. Pirkle, and is often referred to 
as pirkle phase. The chiral stationary phase in brush-type is composed of various 
selectors capable of ionic or covalent bonding. These types of chiral stationary phase 
preceded all the other types of chiral stationary phases historically. The structure of 
these stationary phases is based on a single strand of chiral selectors which posses 
either p-acceptor or p-donor aromatic fragments, together with dipole stacking 
inducing structure and hydrogen bonding agents. These are connected via amidic 
linkage onto aminopropyl silica. 
 
1.10.2 Cyclodextrin columns  
Cyclodextrins are produced by the partial degradation of starch and the enzymatic 
coupling of cleaved glucose unit into crystalline, homogenous toroidal structures of 
different molecular sizes. The α, β and    are the most widely characterized containing 
6, 7 and 8 glucose units respectively which are chiral (Fig 1.23) (Meyer, 2010). The 
cyclodextrin molecules are arranged to form a truncated cone. The cavity in 
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cyclodextrins is composed of glucoside oxygen and methylene hydrogen, giving it an 
apolar character. The external surface of the cavity is hydrophilic surrounded by 
hydroxyl groups. Normal phase type solvents can be used for cyclodextrin but most 
commonly aqueous solutions mixed with organic solvents are used. For chiral 
resolution to occur hydrogen bond region of the molecule must interact with mouth of 
cavity and a portion of molecule must enter hydrophobic cavity. It is important for the 
solute to have one aromatic ring if the separation is of reversed phase type because 
apolar molecule segments become attracted to apolar cavities. Hence cyclodextrin 
based CSP, due to their ability to separate enantiomers of many chiral compounds and 
especially neutral chiral molecules with aromatic units are widely used                 
(Beesley and Scott, 1998). 
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Figure 1.23: The molecular structure of α, β and  cyclodextrins.  (Adapted from 
http://www.chromatography-online.org/Chrial-GC/Contemporary-Chiral-Stationary-
Phases/Cyclodextrin.html). 
 
1.10.3 Ligand exchange phases  
In ligand exchange chiral stationary phases, an amino acid such as L-proline is bonded 
to the silica gel support. This is a general approach to separate enantiomers that forms 
chelates with transition metal ions. Based on its high enantioselectivity chiral ligand 
exchange stationary phase was once the principle method to separate amino acid 
enantiomers (Poole, 2003). Factors such as temperature, ionic strength of mobile 
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phase pH affect the selectivity and efficiency of separation using ligand exchange 
phases. This method is mainly used for separation of α and β amino acids, hydroxy 
acids, amino alcohols and diamines (Gehrke and Wixom, 2010). It can separate such 
compounds because these compounds possess two polar functional groups and 
adequate spacing (Meyer, 2010). Ligand exchange columns are based on interactions 
between enantiomers to be separated during the formation of coordination bonds 
between complex forming metal ion present in solute and stationary phase. The 
differences in stability between complexes with R and S form of a solute result in 
separation of enantiomers. Enantioseparation can be carried out when a stationary 
phase contains chiral ligand metal complex. The metal complex used is mostly Cu2+ 
amino acid complex. For separation to be positive the solute must have two polar 
functional groups with correct spacing that can simultaneously act as ligand for copper 
ion. 
1.10.4 Protein based chiral stationary phase 
Proteins are complex, high molecular weight polymers composed of chiral amino 
acids. In protein based chiral stationary phases separation is based on combination of 
hydrophobic and polar interactions. Their enantioselective properties are based on a 
combination of the bio affinity which is hydrogen bonding, electrostatic interaction 
and hydrophobic interactions. It involves the use of protein immobilized on the surface 
of the silica gel. This protein can be either physically adsorbed or covalently bonded to 
silica gel (Ahuja and Rasmussan, 2007). These phases use stereoselective properties of 
proteins. The four types of proteins used in this kind of separation include bovine 
serum albumin, human serum albumin, ovamucoid proteins and human alpha acid 
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glycoprotein. Protein phases are expensive and delicate in handling and their 
loadabilities and performances are low (Meyer, 2010). 
 
1.10.5 Polysaccharide based stationary phase 
 
Polysaccharide based stationary phases are amongst the most used CSP’s in organics, 
bio organics and pharmaceutical chemistry (Yashima, 2001). They are considered the 
leaders in the chiral separation science due to their remarkable recognition 
capabilities. The main polysaccharides are cellulose, amylose, chitosan, xylan, curdlan, 
dextrin and inulin (Yashima, 2001). Among these, cellulose and amylase approved to 
be the best polymers due to their good capabilities of chiral resolution (Fig 1.24) 
(Okamoto and Yashima, 1997). They consist of D-glucose units linked by 1-4 glucosidic 
bonds. Strands around chiral glucose can be formed by the derivatization of three 
hydroxyls on each glucose unit. The derivatized glucose unit can act as chiral site which 
can discriminate between enantiomers that act differently with strands. The 
derivatized polysaccharide chiral stationary phase supported on silica gel are made by 
the reaction of benzoyl chloride or a phenyl isocyanate with polysaccharide in 
homogenous conditions and by evaporation. These derivatives are then coated from a 
solution onto a macroporous γ-aminopropylsilica matrix (Franco et al., 2001). 
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Figure 1.24: The three dimensional structure of amylose and cellulose (Adapted from- 
http://www.informaworld.com/smpp/section?content=a911179964&fulltext=713240928). 
 
 
The derivatized polysaccharide coated on silica gel was relatively good because its 
chiral selectivity was not affected by dissolving the polysaccharide in organic solvents. 
Selectivity could be enhanced by using various kinds of substituent on the hydroxyl 
group of polysaccharide and by coating them on solid support such as silica support-
aminopropylsilica. The interactions such as π-π interactions, hydrogen bonding,   
dipole-dipole stacking interactions are more effective under normal phase 
chromatography. The polysaccharide type chiral stationary phase can be used with 
normal phase eluents like hexane and ethanol or 2-propanol mixtures. The use of 
alkane: alcohol is possible since there is no ionic functional group in the polysaccharide 
chiral stationary phase and aqueous eluents can be used in reversed phase 
chromatography mode.  
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Figure 1.25: The separation of a mixture of enantiomers using polysaccharide based chiral 
stationary phase (Adapted from http://www.chemistry.or.jp/journals/bcsj/bc-cont/bc77-
2.html). 
 
Although polysaccharide coated on silica gel exhibit high chiral separation abilities they 
are compatible with only a limited number of solvents that can be used as mobile 
phase such as alkanes, alcohols, acetonitrile and their mixtures. Other solvents such as 
ethers, ketones, esters and chlorinated alkanes dissolve the polysaccharide and wash 
off the selector from the silica (Thunberg et al., 2008).  This limited use of solvents is a 
serious disadvantage of these chiral stationary phases, therefore suitable selection of 
solvents is very important for attaining chiral separation. Some of the commonly used 
stationary phases for primary normal phase screening, are Chiralpak AD-H,                
Chiralpak AS-H, Chiralcel OJ-H and Chiralcel OD-H (Ahuja, 2010). These columns can 
resolve a number of structurally different compounds and depict high loading 
capacities making them suitable for application in analytical as well as preparative 
scale resolution of enantiomers (Yamamoto and Okamoto, 2004; Francotte, 2005). 
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1.10.6 Columns used in this study 
 
The three columns used in this study are commercially known as Chiralpak AD-H, 
Chiralcel OD-H and Chiralcel OJ-H columns. Several derivatives are available but these 
three have very complementary properties and numerous publications have 
demonstrated that they are able to achieve a chiral resolution of more than 80 % for 
drugs currently available on the market (Perrin et al., 2002).  
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Figure 1.26: The chemical structure of silica gel used in preparation of Chiralcel OD-H and 
Chiralcel OJ-H columns. 
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Figure 1.27: The chemical structure of silica gel used in preparation of Chiralpak AD-H. 
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1.10.6.1 Chiralpak AD-H 
 
The packing composition of Chiralpak AD-H consist of amylose tris                                   
(3, 5-dimethylphenylcarbamate) coated on 5 µm silica gel. 
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Figure 1.28: The chemical structure of amylose tris (3, 5-dimethylphenylcarbamate) coated on 
silica gel.  
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1.10.6.2 Chiralcel OD-H 
 
The packing composition of Chiralcel OD-H consist of cellulose tris                                      
(3, 5-dimethylphenylcarbamate) coated on a 5µm silica gel. 
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Figure 1.29 The chemical structure of cellulose tris (3, 5-dimethylphenylcarbamate) coated on 
silica gel.  
 
 
 
 
 
 
 
67 
 
1.10.6.3 Chiralcel OJ-H 
 
The packing composition of Chiralcel OJ-H consist of cellulose tris (4-methylbenzoate) 
coated on a 5µm silica gel. 
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Figure 1.30: The chemical structure of cellulose tris (4-methylbenzoate) coated on silica gel.  
 
1.11 Chiral additives 
In the direct separation method chiral additives interact with the solute and form 
some kind of complex. This formation of additive solute complex results in pair of 
diastereomers which has different behaviour patterns in HPLC system. Diastereomers 
show different properties such as interaction with stationary phase and solubility in 
mobile phase. These differences help to separate the enantiomers of the solute. 
Additives are used in chiral HPLC employing polysaccharide based chiral stationary 
68 
 
phases under normal phase conditions (Ye et al., 2004). A maximum of 1 % (v/v) acidic 
and basic additives are frequently incorporated into mobile phases to reduce tailing of 
polar analytes (Tang et al., 1998). Compounds having amine groups require basic 
mobile phase additive such as triethylamine (TEA) and diethylamine (DEA) to avoid 
tailing. These are added to typical hexane: alcohol mixtures to obtain satisfactory 
chiral selectivity, whereas, for acidic compounds acidic additive such as acetic acid and 
trifluoroacetic acid could be used in the mobile phase for better efficiency and elution 
in normal phase mode (Ye et al., 2004).  
 
1.12 Types of liquid chromatography phases 
The two common types of HPLC are normal phase liquid chromatography and reversed 
phase liquid chromatography. These two types can be distinguished on the basis of 
relative polarities of the mobile and stationary phase (Lindsay and Barnes, 1992). 
 
1.12.1 Normal phase liquid chromatography 
Normal phase liquid chromatography being the oldest chromatographic technique 
uses a highly polar stationary phase e.g. silica gel. The mobile phase is a non-polar or a 
low polarity solvent, such as hexane. These solvents are water immiscible and have 
low polarity. This technique separates the molecules based on their strength of 
interaction with the polar stationary phase. These solvents usually are used as a 
mixture. In normal phase liquid chromatography the non polar compounds elute faster 
than the polar compounds (Fig 1.31) (Krupadanam et al., 2001). 
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Figure1.31:  The normal phase chromatographic run, the non polar compound elute 
faster than the polar compound (Adapted from Krupadanam et al., 2001). 
 
1.12.2 Reversed phase liquid chromatography 
In reversed phase liquid chromatography, the stationary phase is non polar such as 
non-polar hydrocarbons, waxy liquids or bonded hydrocarbons such as C18, C8 or C4.  
While the mobile phase is a relatively polar solvent such as methanol, water, 
acetonitrile, or tetrahydrofuran (Skoog and Leary, 1992; Haghedooren et al., 2007). 
There is a wide variety of presently available reversed phase packing system that 
differs by the way they are bonded and their ligand type (Claessen, et al., 1998). In 
reversed phase liquid chromatography the polar compounds elute faster than the             
non- polar compounds (Fig 1.32).  
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Figure1.32: The reversed phase chromatographic run, the polar compound elute faster than 
the non polar compound (Adapted from Krupadanam et al., 2001). 
 
1.13 Elution mode in HPLC 
After choosing an appropriate stationary phase, modifiers and additive, the next most 
important part in liquid chromatography system is to choose an eluent flow mode that 
can provide separations in suitable time scales. There are two modes of elution used 
namely, isocratic and gradient mode (Schellinger and Carr, 2006). These modes of 
separation can employ both normal and reversed phase systems. Isocratic elution is 
performed without changing the mobile phase composition; hence the mobile phase 
composition remains constant throughout the chromatographic run. In gradient mode, 
there are steady changes in the composition of mobile phase. In gradient mode of 
elution desired solvent polarity at specific times can be programmed and 
predetermined (Krupadanam et al., 2001).  
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1.13 The aims and hypothesis of the research 
 
1.13.1 Working hypothesis 
 
Is it possible to develop a chiral HPLC method in order to separate specific 
enantiomers of the anticancer reagent cytarabine using chiral HPLC. 
 
1.13.2 Main aim 
 
The main aim of the project was to utilize and possibly modify the separation of 
specific enantiomers of anticancer reagent cytarabine using chiral HPLC.  
 
1.13.3 Specific aims of the research 
 
1. To develop a HPLC stability-indicating method to separate enantiomers of the    
anticancer reagent cytarabine. 
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CHAPTER 2  
MATERIALS AND METHODS 
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2. MATERIAL AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals and reagents 
 
Chemicals and reagents used in the study are detailed in Table 2.1. All chemicals and 
reagents were of analytical grade and were handled and stored as recommended by 
the suppliers. 
Table 2.1 Chemicals and reagents. 
Name Supplier 
HPLC grade ethanol Fisher scientific (UK) 
HPLC grade n-hexane Fisher scientific (UK) 
HPLC grade 2-propanol Fisher scientific (UK) 
HPLC grade water Fisher scientific (UK) 
HPLC grade acetonitrile Fisher scientific (UK) 
Methylated spirit Fisher scientific (UK) 
Diethyl amine (DEA) Sigma Aldrich (UK) 
Sucrose Sigma Aldrich (UK) 
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2.1.2 Drugs 
 
Drugs used in this study are listed in Table 2.2. 
Table 2.2 Drugs. 
Name Molecular weight Supplier 
Cytarabine 243.22 Sigma Aldrich (UK) 
Trans-stilbene oxide 196.24 Sigma Aldrich (UK) 
 
 
2.1.2.1 Trans-stilbene oxide  
The standard used in this study to test the column efficiency was trans-stilbene oxide.  
O  
Figure 2.1: The chemical structure of trans-stilbene oxide.  
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2.1.3 Equipment 
 
Equipments used in the study are listed in Table 2.3. 
Table 2.3 Equipment.  
 
Equipment Type Supplier 
Analytical balance Balance P/PI-114 Denver instruments (UK) 
Sonicator 
Ultra sonicator-
ULT065 
Ultrawave (UK) 
HPLC Pump Jasco PU-2028 Jasco (UK) 
HPLC Pump Jasco PU-1580 Jasco (UK) 
HPLC Detector Jasco UV-975 Jasco (UK) 
HPLC Detector UV-970M Jasco (UK) 
Quaternary 
Gradient Unit 
LG 1580-04 Jasco (UK) 
HPLC Printer 
Hewlett Packard 
Desk Jet 890C 
Hewlett Packard (UK) 
pH  Meter pH meter 220 S  & M Corning (UK) 
HPLC columns 
Chiralcel OD-H Chiral technologies (Europe) 
Chiralcel OJ-H Chiral technologies (Europe) 
Chiralpak AD-H Chiral technologies (Europe) 
Water bath Nuve water bath nb 5 Biotech lab (Bulgaria) 
Polarimeter Jasco P2000 Jasco (UK) 
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2.2 Methods 
2.2.1 Polarimeter 
The polarimeter used for the measurement of optical rotation of cytarabine was a Jasco 
P2000 (Fig 2.2).  
2.2.1.1 Sample preparation of sucrose for polarimeter 
The sucrose sample was prepared by transferring 5 g of the compound into a 100 ml 
volumetric flask dissolving in water and then making up to the mark with the water to 
afford 5 g % solution of sucrose (0.05 g/ml). 
2.2.1.2 Sample preparation of cytarabine for polarimeter 
The cytarabine sample was prepared for polarimeter by transferring 100 mg of the 
compound into a 10 ml volumetric flask dissolving in water and then making up to the 
mark with the water to afford a concentration of 10 mg/ml. 
 
Figure 2.2: Jasco P2000 polarimeter used for measurement of optical rotation of cytarabine. 
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2.3 HPLC apparatus 
2.3.1 Isocratic flow system 
 
The HPLC system used in the study consisted of a Jasco PU-2028 Intelligent prep pump 
coupled to a UV-975 Intelligent UV/VIS Detector, DEGASYS- DG-3210 degasser, a Nokia 
447ZA plus computer with an AZUR version 5.0.10.0 software package for the 
separation of cytarabine. The printer used was a Hewlett Packard Desk Jet 890C       
(Fig 2.3). 
 
 
 
Figure 2.3: High Performance Liquid Chromatography system used for sample analysis using 
isocratic elution. 
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2.3.2 Gradient flow system 
 
The HPLC system used in the study consisted of a Jasco PU-1580 pump attached to a 
Jasco UV-970M (4-λ intelligent), a Jasco LG 1580-04 Quaternary gradient unit and a 
Viglen Pentium-4 contender with an AZUR version 5.0.10.0 software package for 
separation of cytarabine (Fig. 2.4). The printer used was a Hewlett Packard DeskJet 
890C.  
 
 
Figure 2.4 High Performance Liquid Chromatography used for sample analysis using gradient 
elution. 
 
 
 
 
 
 
 
 
Gradient unit 
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2.3.3 HPLC column 
 
The present work was aimed at investigating the performance of the three chiral 
columns for the enantioseparation of cytarabine. The columns were Chiralcel OD-H, 
Chiralcel OJ-H, and Chiralpak AD-H. The dimensions of all three columns were                   
250 mm x 4.6 mm. 
Table 2.4 Type of chiral columns. 
Column Type of adsorbent 
Particle size 
(µm) 
Chiralcel OD-H Cellulose tris (3,5-dimethylphenylcarbamate) 5  
Chiralcel OJ-H Cellulose tris (4-methylbenzoate) 5  
Chiralpak AD-H Amylose tris (3,5-dimethylphenylcarbamate) 10 
 
The analysis using these columns were carried out only when the column had been 
equilibrated (the time allowed to ensure that the column had equilibrated was 
approximately 30-60 min at a flow rate of 1ml/min). Manual injections were carried 
out using a Rheodyne model 7725i injector with a 20 µl loop. The detector was set to 
monitor at wavelengths 254 nm for all the chromatographic analysis. 
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2.4 Mobile phase used in the analysis of cytarabine 
2.4.1 Mobile phases used for the isocratic flow system 
 
a) Hexane: 2-propanol (v/v) in the ratio of 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 
30:70. 
b) Hexane: ethanol (v/v) in the ratio of 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 
30:70. 
c) Hexane: 2-propanol: diethyl amine (v/v/v) in the ratio of 40: 60: 0.2, 50: 50: 0.2, 
60: 40: 0.2, 70: 30: 0.2. 
d) Hexane:  ethanol: diethyl amine (v/v/v) in the ratio of 40: 60: 0.2, 50: 50: 0.2,      
60: 40: 0.2, 70: 30: 0.2, 80: 20: 0.2.  
e) Acetonitrile: 2-propanol: diethyl amine (v/v/v) in the ratio of 95: 5: 0.2              
(pH - 12.7), 90: 10: 0.2 (pH - 12.2), 85: 15: 0.5 (pH - 12.5). 
f) Acetonitrile: ethanol: diethyl amine (v/v/v) in the ratio of 95: 5: 0.2 (pH - 12.2), 
90: 10: 0.2 (pH - 12.0), 85: 15: 0.5 (pH - 12.0). 
The mobile phases were sonicated and filtered before use and each of the 
composition was run at flow rates of 0.5, 1.0 and 1.5 ml/min. 
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2.4.2 The mobile phase combinations used for the Gradient system using Chiralpak 
AD-H column 
Varying combinations of hexane and alcohol (2-propanol or ethanol) were used.  
a.  
 
 
Figure 2.5: The gradient conditions ranging from 5 % to 10 % of 2-propanol in 30 
min.  MP ratio – hexane: 2-propanol. 
 
 
 
b. 
                    
 
 
Figure 2.6: The gradient conditions ranging from 5 % to 10 % of ethanol in             
40 min. MP ratio – hexane: ethanol. 
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c. 
 
 
 
Figure 2.7: The gradient conditions from 10 % to 15 % of alcohol in 22 min.      
MP ratio – hexane: alcohol (2-propanol or ethanol). 
 
 
 
 
 
 
 
d. 
 
 
Figure 2.8: The gradient conditions for 15 % to 20 % of alcohol in 22 min. MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
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e. 
 
 
Figure 2.9:  The gradient conditions for 20 % to 25 % of alcohol in 22 min.  MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
 
 
 
 
f. 
 
 
Figure 2.10: The gradient conditions from 25 % to 30 % of alcohol in 22 min. MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
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g.  
 
 
         
 
 
Figure 2.11: The gradient conditions from 30 % to 35 % of alcohol in 22 min. MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
 
 
  
 
 
 
h. 
 
 
       
 
Figure 2.12: The gradient conditions for 35 % to 40 % of alcohol in 22 min. MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
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i. 
 
 
Figure 2.13: The gradient conditions for 40 % to 45 % of alcohol in 22 min. MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
 
 
 
j. 
 
 
                                       
Figure 2.14: The gradient conditions for 10 % to 35 % of alcohol in 17 min. MP 
ratio – hexane: alcohol (2-propanol or ethanol). 
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The two alcohols used as organic modifier in hexane are 2-propanol and ethanol 
individually. The flow rate was held constant at 1.0 ml/min for all gradients, except for 
the mobile phase ratio ranging from (hexane: 2-propanol) 70:30 to 65:35 where two 
different flow rates of 0.5 ml/min and 1 ml/min were employed. All samples were 
injected after 30 min of isocratic equilibration. These mobile phases used in both 
isocratic and gradient conditions were sonicated, filtered & degassed before running it 
through the HPLC system. 
2.5 Stock solution 
The stock solution of cytarabine was prepared by transferring 10 mg of the compound 
into a 100 ml volumetric flask dissolving in a mixture of ethanol and 2-propanol (1:1) 
and then making up to the mark using the same composition of alcohol providing a 
final concentration of 10 mg % (0.1 mg/ml).  
2.6 Sample preparation of trans-stilbene oxide 
 
The trans-stilbene oxide sample was prepared by transferring 10 mg of the compound 
into a 10 ml volumetric flask dissolving in a mixture of hexane: 2-propanol (9:1) and 
then making up to the mark with the same composition of hexane and 2-propanol to 
afford a final concentration 1 mg/ml.  
All the stock solutions were stored in the refrigerator at 4°C until further use.  
2.7 Statistical analysis 
For all the methods used for enantioseparation of anticancer reagent cytarabine, the 
experiments were performed in triplicate, and the results were expressed as the mean 
±Standard Deviation (SD) from the three or four independent experiments, relative 
standard deviation (RSD) was calculated using where necessary. The data analysis was 
performed using SPSS version 18.0.3 and Microsoft Excel. 
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3. RESULTS 
 
3.1 Polarimeter results 
 
The optical rotation for the anticancer reagent cytarabine was determined using 
polarimeter. Sucrose was used as a standard to check the performance of the 
polarimeter. 
 
Table 3.1: Showing the optical and specific rotation of sucrose and cytarabine. Data 
values ± standard deviation. 
 
Compound 
Observed rotation 
n = 5 
RSD Specific rotation 
 
Sucrose 3.2906 ± 0.0003 0.009  (+) 65.79 
Cytarabine 1.5584 ± 0.0023 0.147    (+) 153.68 
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3.2 HPLC column performance 
Column performance was regularly monitored for the three columns Chiralcel OD-H, 
OJ-H and Chiralpak AD-H by checking the resolution of trans-stilbene oxide as 
standard. 
A. 
 
 
B. 
 
Figure 3.1: HPLC chromatogram showing the results for trans-stilbene oxide using 90% 
hexane and 10% 2-propanol (a) at a flow rate 0.5 ml/min on the Chiralcel OD-H column 
and (b) at a flow rate 1.0 ml/min on the Chiralcel OJ-H column. 
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C. 
 
Figure 3.2: HPLC chromatogram showing the result for trans-stilbene oxide using 90% 
hexane and 10% 2-propanol at a flow rate 0.5 ml/min on the Chiralpak AD-H column. 
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3.3 The HPLC method using hexane: 2-propanol (v/v) 
 
Chromatographic conditions- Chromatographic separation of cytarabine enantiomers 
was carried out using isocratic conditions at an ambient temperature, unless 
otherwise specified. Combinations of hexane: 2-propanol was used as the mobile 
phase. The flow rates used were 0.5, 1.0 and 1.5 ml/min and the cytarabine at a 
concentration of 10 mg % dissolved in a mixture of 2-propanol: ethanol (1:1) (v/v) was 
used. The injection volume was kept constant at 20 µl. 
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3.3.1 HPLC results for Chiralcel OD-H using hexane: 2-propanol (v/v) 
 
The separation of enantiomers of cytarabine (10 mg %) was carried out using a 
mixture ranging from (90:10) to (30:70) (v/v) at flow rates of 0.5, 1.0 and 1.5 ml/min 
on the Chiralcel OD-H column. A significant decrease was observed in the retention 
time of cytarabine with increasing concentrations of 2-propanol. 
Table 3.2: Effect of 2-propanol on selectivity and resolution of cytarabine enantiomers 
using the Chiralcel OD-H column at three different flow rates. Data values ± standard 
deviation. 
 
MOBILE PHASE 
HEXANE:IPA (v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
90:10 
0.5 106.20 2182 ± 19.17 
1 54.60 1143 ± 11.43 
1.5 32.21 870 ± 22.11 
80:20 
0.5 19.80 6781 ± 13.16 
1 10.20 3034 ± 20.70 
1.5 6.22 2531 ± 36.05 
70:30 
0.5 11.02 6422 ± 88.33 
1 5.35 3862 ± 27.23 
1.5 3.48 2772 ± 18.82 
60:40 
0.5 8.08 7391 ± 22.07 
1 4.15 3972 ± 20.73 
1.5 2.65 2977 ± 20.32 
50:50 
0.5 7.28 7677 ± 17.28 
1 3.85 4045 ± 26.20 
1.5 2.40 3044 ± 12.24 
40:60 
0.5 6.90 7252 ± 4.45 
1 3.47 4067 ± 54.33 
1.5 2.27 2979 ± 36.81 
30:70 
0.5 6.45 6753 ± 47.11 
1 3.32 4078 ± 21.33 
1.5 2.20 2969 ± 20.43 
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3.3.2 HPLC results for Chiralcel OJ-H using hexane: 2-propanol (v/v) 
 
The separation of enantiomers of cytarabine (10 mg %) was carried out using a 
mixture ranging from (90:10) to (30:70) (v/v) with flow rates of 0.5, 1.0 and 1.5 ml/min 
on the Chiralcel OJ-H column. A significant decrease was observed in the retention 
time of cytarabine with increasing concentration of 2-propanol. Partial separation was 
obtained using ratios 40:60 (Fig. 3.9), 50:50 (Fig. 3.6) and 70:30 (Fig. 3.4).  
Table 3.3: Effect of 2-propanol on the selectivity and resolution of cytarabine 
enantiomers on the Chiralpak OJ-H column at three different flow rates. Data values ± 
standard deviation. 
 
MOBILE PHASE 
HEXANE:IPA (v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
90:10 
0.5 24.30 4596 ± 60.35 
1 11.47 3009 ± 126.21 
1.5 7.62 2197 ± 59.76 
80:20 
0.5 8.98 6718 ± 19.94 
1 4.47 3551 ± 166.40 
1.5 2.97 2378 ± 37.18 
70:30 
0.5 7.55 5301 ± 56.27 
1 
3.57 1091 ± 28.11 
3.77 2312 ± 68.36 
1.5 2.38 2399 ± 19.42 
60:40 
0.5 7.05 5722 ± 22.98 
1 3.58 3554 ± 69.10 
1.5 2.28 2443 ± 32.45 
50:50 
0.5 
6.58 2979 ± 51.37 
6.88 1756 ± 73.69 
1 3.28 3436 ± 192.27 
1.5 2.23 2358 ± 31.06 
40:60 
0.5 
6.42 3503 ± 40.65 
6.77 1554 ± 5.42 
1 3.28 3171 ± 97.76 
1.5 2.17 2273 ± 110.01 
30:70 
0.5 6.02 3248 ± 65.43 
1 2.95 1668 ± 78.56 
1.5 2.04 1011 ± 37.36 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol (v/v) (70:30) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 
ml/min (C) on the Chiralcel OJ-H column. 
A. 
 
Figure 3.3: HPLC chromatogram showing the result for cytarabine using 70 % hexane 
and 30 % 2-propanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
 
 
B. 
 
Figure 3.4: HPLC chromatogram showing the result for cytarabine using 70 % hexane 
and 30 % 2-propanol at a flow rate 1.0 ml/min on the Chiralcel OJ-H column. 
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C. 
 
Figure 3.5: HPLC chromatogram showing the result for cytarabine using 70 % hexane 
and 30 % 2-propanol at a flow rate 1.5 ml/min on the Chiralcel OJ-H column. 
 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol (v/v) (50:50) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 
ml/min (C) on the Chiralcel OJ-H column. 
 
A. 
 
Figure 3.6: HPLC chromatogram showing the result for cytarabine using 50 % hexane 
and 50 % 2-propanol at a flow rate of 0.5 ml/min on the Chiralcel OJ-H column. 
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B. 
 
Figure 3.7: HPLC chromatogram showing the result for cytarabine using 50 % hexane 
and 50 % 2-propanol at a flow rate of 1.0 ml/min on the Chiralcel OJ-H column. 
 
 
C. 
 
Figure 3.8: HPLC chromatogram showing the result for cytarabine using 50 % hexane 
and 50 % 2-propanol at a flow rate of 1.5 ml/min on the Chiralcel OJ-H column. 
 
 
 
97 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol (v/v) (40:60) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 
ml/min (C) on the Chiralcel OJ-H column. 
A. 
 
Figure 3.9: HPLC chromatogram showing the result for cytarabine using 40 % hexane 
and 60 % 2-propanol at a flow rate of 0.5 ml/min on the Chiralcel OJ-H column. 
 
 
B. 
 
Figure 3.10: HPLC chromatogram showing the result for cytarabine using 40 % hexane 
and 60 % 2-propanol at a flow rate of 1.0 ml/min on the Chiralcel OJ-H column. 
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C. 
 
Figure 3.11: HPLC chromatogram showing the result for cytarabine using 40 % hexane 
and 60 % 2-propanol at a flow rate of 1.5 ml/min on the Chiralcel OJ-H column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
3.3.3 HPLC results for Chiralpak AD-H using hexane: 2-propanol (v/v) 
The separation of enantiomers of cytarabine (10 mg %) was carried out using a 
mixture ranging from (90:10) to (30:70) (v/v) with flow rates of 0.5, 1.0 and 1.5 ml/min 
on the Chiralpak AD-H column. Partial separation was achieved using mobile phase 
ratios of 50:50 (Fig. 3.20), 60:40 (Fig. 3.17) and 70:30 (Fig. 3.14).  
Table 3.4: Effect of 2-propanol on selectivity and resolution of cytarabine enantiomers 
on the Chiralpak AD-H column at three different flow rates. Data values ± standard 
deviation. 
MOBILE PHASE 
HEXANE:IPA (v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
90:10 0.5 41.88 4103 ± 66.66 
1 24.21 2715 ± 261.18 
1.5 15.23 1133 ± 38.42 
80:20 0.5 10.75 5432 ± 163.03 
1 5.37 3681 ± 170.17 
1.5 3.69 2565 ± 98.87 
70:30 0.5 7.28 1046 ± 37.72 
7.68 4090 ± 62.08 
1 3.57 840 ± 18.58 
3.82 2375 ± 115.11 
1.5 2.38 1103 ± 11.21 
2.57 1337 ± 183.90 
60:40 0.5 6.63 1198 ± 50.29 
6.98  2886 ± 89.62 
1 3.25 1301 ± 230.77 
3.60 2569 ± 363.87 
1.5 2.18 1315 ± 20.11 
2.43 1093 ± 23.05 
50:50 0.5 6.10 611 ± 15.29 
6.52 5629 ± 104.24 
1 3.13 3457 ± 74.62 
1.5 2.08 1230 ± 75.48 
2.30 1184 ± 57.33 
40:60 0.5 6.37 6094 ± 57.25 
1 3.18 3382 ± 26.10 
1.5 2.02  2427 ± 30.45 
30:70 0.5 5.97 5845 ± 15.43 
1 3.21 2968 ± 36.81 
1.5 2.01 1946 ± 11.08 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol (v/v) (70:30) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 
ml/min (C) on the Chiralpak AD-H column. 
A. 
 
Figure 3.12: HPLC chromatogram showing the result for cytarabine using 70 % hexane 
and 30 % 2-propanol at a flow rate 0.5 ml/min on the Chiralpak AD-H column. 
 
 
B. 
 
Figure 3.13: HPLC chromatogram showing the result for cytarabine using 70 % hexane 
and 30 % 2-propanol at a flow rate 1.0 ml/min on the Chiralpak AD-H column. 
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C. 
 
Figure 3.14: HPLC chromatogram showing the result for cytarabine using 70 % hexane 
and 30 % 2-propanol at a flow rate 1.5 ml/min on the Chiralpak AD-H column. 
 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol (v/v) (60:40) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 
ml/min (C) on the Chiralpak AD-H column. 
 
A. 
 
Figure 3.15: HPLC chromatogram showing the result for cytarabine using 60 % hexane 
and 40 % 2-propanol at a flow rate 0.5 ml/min on the Chiralpak AD-H column. 
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B. 
 
Figure 3.16: HPLC chromatogram showing the result for cytarabine using 60 % hexane 
and 40 % 2-propanol at a flow rate 1.0 ml/min on the Chiralpak AD-H column. 
 
 
C. 
 
Figure 3.17: HPLC chromatogram showing the result for cytarabine using 60 % hexane 
and 40 % 2-propanol at a flow rate 1.5 ml/min on the Chiralpak AD-H column. 
 
 
 
 
 
 
103 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol (v/v) (50:50) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 
ml/min (C) on the Chiralpak AD-H column. 
A. 
 
Figure 3.18: HPLC chromatogram showing the result for cytarabine using 50% hexane 
and 50% 2-propanol at a flow rate 0.5 ml/min on the Chiralpak AD-H column. 
 
 
B. 
 
Figure 3.19: HPLC chromatogram showing the result for cytarabine using 50% hexane 
and 50% 2-propanol at a flow rate 1.0 ml/min on the Chiralpak AD-H column. 
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C. 
 
Figure 3.20: HPLC chromatogram showing the result for cytarabine using 50% hexane 
and 50% 2-propanol at a flow rate 1.5 ml/min on the Chiralpak AD-H column. 
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3.4 HPLC method using hexane and ethanol (v/v) 
 
Chromatographic conditions - The chromatographic separation of cytarabine 
enantiomers was carried out using an isocratic system at ambient temperature, unless 
otherwise specified. A combination of hexane: ethanol ranging from (90:10) to (30:70) 
(v/v) was used as mobile phase with flow rates of 0.5, 1.0 and 1.5 ml/min.  Cytarabine 
at a concentration of 10 mg % dissolved in a mixture of 2-propanol: ethanol (1:1) was 
used. The injection volume was kept constant at 20 µl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
3.4.1 HPLC results for Chiralcel OD-H using hexane: ethanol (v/v) 
 
The separation of enantiomers of cytarabine (10 mg %) was carried out with flow rates 
of 0.5, 1.0 and 1.5 ml/min on the Chiralcel OD-H column. A significant decrease was 
observed in the retention time of cytarabine with increasing concentrations of 
ethanol.  
Table 3.5: Effect of ethanol on the selectivity and resolution of cytarabine enantiomers 
using Chiralcel OD-H column at three different flow rates. Data values ± standard 
deviation. 
 
MOBILE PHASE 
HEXANE: EtOH (v/v) 
 
FLOW RATE 
(ml/min) 
RETENTION 
TIME 
(min) 
MEAN PEAK AREA 
n = 3 
90:10 
0.5 41.05 4568 ± 19.92 
1 20.58 2745  ± 38.06 
1.5 13.27 2135  ± 22.32 
80:20 
0.5 13.32 5818  ± 18.56 
1 6.43 3643 ± 18.15 
1.5 4.28 2413  ± 17.05 
70:30 
0.5 8.53 6788  ± 13.21 
1 4.22 3933  ± 17.27 
1.5 2.80 3038  ± 19.90 
60:40 
0.5 7.30 6353  ± 30.61 
1 3.68 4160  ± 36.88 
1.5 2.74 2759  ± 19.02 
50:50 
0.5 6.82 6974  ± 24.86 
1 3.53 4231  ± 17.97 
1.5 2.27 2953  ± 27.69 
40:60 
0.5 6.08 8306  ± 8.48 
1 3.15 4485  ± 27.29 
1.5 2.10 2918  ± 22.26 
30:70 
0.5 6.22 6315  ± 23.13 
1 3.12 4420  ± 37.56 
1.5 2.13 2955 ± 29.49 
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3.4.2 HPLC results for Chiralcel OJ-H using hexane: ethanol (v/v) 
Attempted Separation of enantiomers of cytarabine (10 mg %) with flow rates of 0.5, 
1.0 and 1.5 ml/min on Chiralcel OJ-H column. A significant decrease in the retention 
time of cytarabine was observed with increasing concentrations of ethanol. Partial 
separation was obtained using ratios 40:60 (Fig. 3.30), 50:50 (Fig. 3.27), 60:40 
(Fig.3.24) and 70:30 (3.21).  
Table 3.6: Effect of ethanol on selectivity and resolution of cytarabine enantiomers on 
the Chiralcel OJ-H column at three different flow rates. Data values ± standard 
deviation. 
 
MOBILE PHASE 
HEXANE:EtOH (v/v) 
FLOW RATE 
(ml/min) 
RETENTION 
TIME 
(min) 
MEAN PEAK AREA 
n = 3 
90:10 
0.5 22.95 5940 ± 42.95 
1 11.40 3214 ± 117.12 
1.5 7.25 2354 ± 65.13 
80:20 
0.5 8.98 6046 ± 51.08 
1 4.47 3417 ± 127.28 
1.5 2.90 2373 ± 123.86 
70:30 
0.5 
7.35 2087 ± 172.85 
7.65 2513 ± 113.90 
1 3.85 3240 ± 29.28 
1.5 2.52 2482 ± 147.91 
60:40 
0.5 
6.96 3873 ± 26.15 
7.23 1813 ±16.58 
1 3.45 3464 ± 41.93 
1.5 2.32 2486 ± 197.69 
50:50 
0.5 
6.57 3131 ± 97.61 
6.93 3028 ±76.89 
1 3.43 3343 ±138.46 
1.5 2.25 2378 ± 86.03 
40:60 
0.5 
6.33 4525 ± 88.42 
6.83 2080 ± 69.20 
1 3.33 3550 ± 116.00 
1.5 2.15 2464 ± 39.27 
30:70 
0.5 6.13 4770 ±123.08 
1 3.10 3463 ± 133.64 
1.5 2.15 2313 ± 162.18 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (70:30) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralcel OJ-H column. 
 
A. 
 
Figure 3.21: HPLC chromatogram showing the result for cytarabine with 70 % hexane 
and 30 % ethanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
 
 
B. 
 
Figure 3.22: HPLC chromatogram showing the result for cytarabine with 70 % hexane 
and 30 % ethanol at a flow rate 1.0 ml/min on the Chiralcel OJ-H column. 
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C. 
 
Figure 3.23: HPLC chromatogram showing the result for cytarabine with 70 % hexane 
and 30 % ethanol at a flow rate 1.5 ml/min on the Chiralcel OJ-H column. 
 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (60:40) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralcel OJ-H column. 
 
A. 
 
Figure 3.24: HPLC chromatogram showing the result for cytarabine with 60 % hexane 
and 40 % ethanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
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B. 
 
Figure 3.25: HPLC chromatogram showing the result for cytarabine with 60 % hexane 
and 40 % ethanol at a flow rate 1.0ml/min on the Chiralcel OJ-H column. 
 
 
C. 
 
Figure 3.26: HPLC chromatogram showing the result for cytarabine with 60 % hexane 
and 40 % ethanol at a flow rate 1.5 ml/min on the Chiralcel OJ-H column. 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (50:50) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralcel OJ-H column. 
 
A. 
 
Figure 3.27: HPLC chromatogram showing the result for cytarabine with 50 % hexane 
and 50 % ethanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
 
 
B. 
 
Figure 3.28: HPLC chromatogram showing the result for cytarabine with 50% hexane 
and 50% ethanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
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C. 
 
Figure 3.29: HPLC chromatogram showing the result for cytarabine with 50% hexane 
and 50% ethanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (40:60) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralcel OJ-H column. 
 
A. 
 
Figure 3.30: HPLC chromatogram showing the result for cytarabine with 40% hexane 
and 60% ethanol at a flow rate 0.5 ml/min on the Chiralcel OJ-H column. 
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B. 
 
Figure 3.31: HPLC chromatogram showing the result for cytarabine with 40% hexane 
and 60% ethanol at a flow rate 1.0 ml/min on the Chiralcel OJ-H column. 
 
 
C. 
 
Figure 3.32: HPLC chromatogram showing the result for cytarabine with 40% hexane 
and 60% ethanol at a flow rate 1.5 ml/min on the Chiralcel OJ-H column. 
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3.4.3 HPLC results for Chiralpak AD-H using hexane: ethanol (v/v) 
Attempted separation of enantiomers of cytarabine (10 mg %) with flow rates of 0.5, 
1.0 and 1.5 ml/min on the Chiralpak AD-H column. Partial separation was achieved 
using a mobile phase ratios 50:50 (Fig. 3.39 & 3.40), 60:40 (Fig. 3.36, 3.37 & 3.38) and 
80:20 (Fig. 3.33 & 3.34).  
Table 3.7: Effect of ethanol on the selectivity and resolution of cytarabine enantiomers 
using the Chiralpak AD-H column at different flow rates. Data values ± standard 
deviation.                                                                                                                                                                                         
MOBILE PHASE  
HEXANE:EtOH (v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3  
90/10 
0.5 8.21 6954 ± 33.03 
1 4.73 3298 ± 79.32 
1.5 2.43 1475 ± 19.74 
80/20 
0.5 
13.07 2513 ± 109.67 
13.52 3203 ± 72.53 
1 
6.38 1461 ± 66.42 
6.67 1844 ± 113.62 
1.5 4.38 2330 ± 56.68 
70/30 
0.5 8.22 5192 ± 60.64 
1 4.08 3550 ± 76.60 
1.5 2.70 2328 ± 50.63 
60/40 
0.5 
6.70 1403 ± 65.05 
7.08 4995 ± 45.21 
1 
3.48 4921 ± 65.86 
3.68 2247 ± 92.22 
1.5 
2.30 1478 ± 128.79 
2.47 2469 ± 17.78 
50/50 
0.5 
6.50 3521 ± 45.91 
6.82 2737 ± 67.54 
7.10 727 ± 7.74 
1 
3.37 1936 ± 35.62 
3.57 1492 ± 38.41 
1.5 2.20 2407 ± 34.15 
40/60 
0.5 6.57 6196 ± 33.21 
1 3.23 3574 ± 172.12 
1.5 2.15 2443 ± 25.81 
30/70 
0.5 5.95 5535.80 ± 81.40 
1 3.10 2958.34 ± 20.29 
1.5 2.85 1544.74 ± 4.32 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (80:20) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralpak AD-H column. 
 
A. 
 
Figure 3.33: HPLC chromatogram showing the result for cytarabine with 80 % hexane 
and 20 % ethanol at flow rate 0.5 ml/min on the Chiralpak AD-H column. 
 
 
B. 
 
Figure 3.34: HPLC chromatogram showing the result for cytarabine with 80 % hexane 
and 20 % ethanol at flow rate 1.0 ml/min on the Chiralpak AD-H column. 
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C. 
 
Figure 3.35: HPLC chromatogram showing the result for cytarabine with 80 % hexane 
and 20 % ethanol at flow rate 1.5 ml/min on the Chiralpak AD-H column. 
 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (60:40) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralpak AD-H column. 
A. 
 
Figure 3.36: HPLC chromatogram showing the result for cytarabine with 60 % of 
hexane and 40 % ethanol at flow rate 0.5 ml/min on the Chiralpak AD-H column. 
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B. 
 
Figure 3.37: HPLC chromatogram showing the result for cytarabine with 60 % of 
hexane and 40 % ethanol at flow rate 1.0 ml/min on the Chiralpak AD-H column. 
 
 
C. 
 
Figure 3.38: HPLC chromatogram showing the result for cytarabine with 60 % of 
hexane and 40 % ethanol at flow rate 1.5 ml/min on the Chiralpak AD-H column. 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol (v/v) (50:50) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 1.5 ml/min 
(C) on the Chiralpak AD-H column. 
 
A. 
 
Figure 3.39: HPLC chromatogram showing the result for cytarabine 50 % of hexane and 
50 % ethanol at flow rate 0.5 ml/min on the Chiralpak AD-H column. 
 
 
B. 
 
Figure 3.40: HPLC chromatogram showing the result for cytarabine 50 % of hexane and 
50 % ethanol at flow rate 1.0 ml/min on the Chiralpak AD-H column. 
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C. 
 
Figure 3.41: HPLC chromatogram showing the result for cytarabine 50 % of hexane and 
50 % ethanol at flow rate 1.5 ml/min on the Chiralpak AD-H column. 
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3.5 HPLC method for selectivity and resolution of cytarabine enantiomers on 
Chiralcel OJ-H and Chiralpak AD-H columns using chiral modifier diethylamine (DEA) 
 
The Chiralcel OJ-H and Chiralpak AD-H columns were used with different ratios of       
2-propanol and ethanol as organic modifiers in hexane together with a basic modifier 
DEA. The selectivity of these two columns as well as the effect of the mobile phase 
characteristics on the retention and resolution of cytarabine enantiomers was 
investigated. The cytarabine was analysed at a wavelength of 254 nm. 
 
Chromatographic conditions - Chromatographic separation of cytarabine enantiomers 
was carried out using an isocratic system at ambient temperature, unless otherwise 
specified. A combination of hexane: 2-propanol: DEA (0.2 %) (v/v/v) and                    
hexane: ethanol: DEA (0.2 %) (v/v/v). DEA was added to various ratios which resulted 
in improved resolution using hexane: 2-propanol or ethanol with the three columns. 
Cytarabine was prepared at 10 mg % dissolved in a mixture of (1:1)                                   
2-propanol: ethanol. The injection volume was kept constant at 20 µl. 
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3.5.1 HPLC results for Chiralcel OJ-H using hexane: 2-propanol: DEA (v/v/v) 
 
From the results of using varying combinations of hexane: 2-propanol on the Chiralcel 
OJ-H column, the most promising conditions were chosen and repeated with the 
addition of DEA. Partial separation was achieved using the ratios 50:50:0.2 v/v/v       
(Fig 3.43), and 70:30:0.5 v/v/v (Fig 3.46 and 3.47). 
 
Table 3.8: Effect of DEA on the selectivity and resolution of cytarabine enantiomers 
using three selected ratios of hexane and 2-propanol on the Chiralcel OJ-H column at 
three different flow rates. Data values ± standard deviation. 
 
MOBILE PHASE 
HEXANE:IPA:DEA 
(v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
40: 60: 0.2 
0.5 6.30 6108 ± 162.93 
1 3.22 3776  ± 121.41 
1.5 2.15 2816  ± 56.61 
50: 50: 0.2 
0.5 
6.40 2060 ±119.38 
6.78 4534  ± 82.61 
1 3.33 4230  ± 97.16 
1.5 2.22 2813  ±123.13 
70: 30: 0.2 
0.5 
6.48 3275  ± 81.75 
6.92 2158  ± 106.54 
1 
3.27 1817  ± 24.79 
3.47 2235  ± 71.26 
1.5 2.23 2782  ± 107.32 
 
 
 
 
 
 
 
122 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol: DEA (v/v/v) (50:50:0.2) at flow rate 0.5 ml/min (A), 1 ml/min(B) 
and 1.5 ml/min (C) on the Chiralcel OJ-H column. 
A. 
 
Figure 3.42: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % 2-propanol and 0.2 % DEA at flow rate 0.5 ml/min on the              
Chiralcel OJ-H column. 
 
B. 
 
Figure 3.43: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % 2-propanol and 0.2 % DEA at flow rate 1.0 ml/min on the Chiralcel 
OJ-H column. 
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C. 
 
Figure 3.44: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % 2-propanol and 0.2 % DEA at flow rate 1.5 ml/min on the Chiralcel 
OJ-H column. 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol: DEA (v/v/v) (70:30:0.2) at flow rate 0.5 ml/min (A), 1 ml/min(B) 
and 1.5 ml/min (C) on the Chiralcel OJ-H column. 
A. 
 
Figure 3.45: HPLC chromatogram showing the result for cytarabine using 70 % of 
hexane and 30 % 2-propanol and 0.2 % DEA at flow rate 0.5 ml/min on the Chiralcel 
OJ-H column. 
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B. 
 
Figure 3.46: HPLC chromatogram showing the result for cytarabine using 70 % of 
hexane and 30 % 2-propanol and 0.2 % DEA at flow rate 1.0 ml/min on the Chiralcel 
OJ-H column. 
 
 
C. 
 
Figure 3.47: HPLC chromatogram showing the result for cytarabine using 70 % of 
hexane and 30 % 2-propanol and 0.2 % DEA at flow rate 1.5 ml/min on the Chiralcel 
OJ-H column. 
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3.5.2 HPLC results for the Chiralcel OJ-H using hexane: ethanol: DEA (v/v/v) 
 
From the results using varying combinations of hexane: ethanol on the Chiralcel OJ-H 
column, the most promising conditions were chosen and repeated with the addition of 
DEA. Partial separation was achieved using ratios 50:50:0.2 v/v/v (Fig 3.49) and                  
60:40:0.5 v/v/v (Fig 3.52). 
 
Table 3.9: Effect of ethanol and DEA on the selectivity and resolution of cytarabine 
enantiomers using selected ratios of hexane and ethanol on the Chiralcel OJ-H column 
at three different flow rates. Data values ± standard deviation. 
 
MOBILE PHASE 
HEXANE:EtOH:DEA 
(v/v/v) 
 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
50:50:0.2 
0.5 
6.78 5745  ± 191.92 
7.17 905  ± 5.53 
1 3.37 3702  ± 121.53 
1.5 2.22 2558  ± 150.06 
60:40:0.2 
 
0.5 
6.65 2135  ± 110.57 
7.20 2326  ± 109.38 
1 3.53 3663  ± 141.41 
1.5 2.28 2363  ± 115.94 
70:30:0.2 
0.5 7.47 6115 ± 147.45 
1 3.80 3779  ± 140.35 
1.5 2.47 2593  ± 81.60 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol: DEA (v/v/v) (50:50:0.2) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 
1.5 ml/min (C) on the Chiralcel OJ-H column. 
A. 
 
Figure 3.48: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % ethanol and 0.2 % DEA at flow rate 0.5 ml/min on the Chiralcel OJ-H 
column. 
 
B. 
 
Figure 3.49: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % ethanol and 0.2 % DEA at flow rate 1.0 ml/min on the Chiralcel OJ-H 
column. 
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C. 
 
Figure 3.50: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % ethanol and 0.2 % DEA at flow rate 1.5 ml/min on the Chiralcel OJ-H 
column. 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: ethanol: DEA (v/v/v) (60:40:0.2) at flow rate 0.5 ml/min (A), 1 ml/min(B) and 
1.5 ml/min (C) on the Chiralcel OJ-H column. 
A. 
 
Figure 3.51: HPLC chromatogram showing the result for cytarabine using 60 % of 
hexane and 40 % ethanol and 0.2 % DEA at flow rate 0.5 ml/min on the Chiralcel OJ-H 
column. 
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B. 
 
Figure 3.52: HPLC chromatogram showing the result for cytarabine using 60 % of 
hexane and 40 % ethanol and 0.2 % DEA at flow rate 1.0 ml/min on the Chiralcel OJ-H 
column. 
 
 
C. 
 
Figure 3.53: HPLC chromatogram showing the result for cytarabine using 60 % of 
hexane and 40 % ethanol and 0.2 % DEA at flow rate 1.5 ml/min on the Chiralcel OJ-H 
column. 
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3.5.3 HPLC results for Chiralpak AD-H using hexane: 2-propanol: DEA (v/v/v) 
 
From the results using varying combinations of hexane: 2-propanol on the Chiralpak 
AD-H column, the most promising combinations were chosen and repeated with the 
addition of DEA. Partial separation was achieved using the ratios of 50:50:0.2 v/v/v          
(Fig 3.56) and 60:40:0.5 v/v/v (Fig 3.58, 3.59. 3.60). 
                                 
Table 3.10: Effect of 2-propanol and DEA on the selectivity and resolution of 
cytarabine enantiomers on the Chiralpak AD-H column at three different flow rates. 
Data values ± standard deviation. 
 
MOBILE PHASE 
HEXANE: IPA: DEA 
(v/v/v) 
 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
50:50:0.2 
0.5 
6.10 1076 ± 51.87 
6.72 4939 ± 51.89 
1 
3.10 1186 ± 60.59 
3.40 2254 ± 88.48 
1.5 2.07 2420 ± 45.89 
60:40:0.2 
0.5 
6.28 854 ± 4.61 
6.65 1622 ± 22.25 
6.95 1506 ± 5.37 
7.20 1344 ± 33.83 
1 
3.18 1154 ± 95.86 
3.57 2330 ± 99.72 
1.5 
2.15 1501 ± 62.58 
2.42 870 ± 31.45 
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Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol: DEA (v/v/v) (50:50:0.2) at flow rate 0.5 ml/min (A), 1 ml/min(B) 
and 1.5 ml/min (C) on the Chiralpak AD-H column. 
A. 
 
Figure 3.54: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % 2-propanol and 0.2% DEA at flow rate 0.5 ml/min on the Chiralpak 
AD-H column. 
 
B. 
 
Figure 3.55: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % 2-propanol and 0.2% DEA at flow rate 1.0 ml/min on the Chiralpak 
AD-H column. 
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C. 
 
Figure 3.56: HPLC chromatogram showing the result for cytarabine using 50 % of 
hexane and 50 % 2-propanol and 0.2% DEA at flow rate 1.5 ml/min on the Chiralpak 
AD-H column. 
 
Chromatograms showing partial resolution of cytarabine enantiomers using                
hexane: 2-propanol: DEA (v/v/v) (60:40:0.2) at flow rate 0.5 ml/min (A), 1 ml/min(B) 
and 1.5 ml/min (C) on the Chiralpak AD-H column. 
A. 
 
Figure 3.57: HPLC chromatogram showing the result for cytarabine using 60 % of 
hexane and 40 % 2-propanol and 0.2% DEA at flow rate 0.5 ml/min on the Chiralpak 
AD-H column. 
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B. 
 
Figure 3.58: HPLC chromatogram showing the result for cytarabine using 60 % of 
hexane and 40 % 2-propanol and 0.2 % DEA at flow rate 1.0 ml/min on the Chiralpak 
AD-H column. 
 
C. 
 
Figure 3.59: HPLC chromatogram showing the result for cytarabine using 60 % of 
hexane and 40 % 2-propanol and 0.2 % DEA at flow rate 1.5 ml/min on the Chiralpak 
AD-H column. 
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3.5.4 HPLC results for Chiralpak AD-H using hexane: ethanol: DEA (v/v/v) 
 
From the results using varying combinations of hexane: ethanol on the Chiralpak AD-H 
column (Table 3), the most promising combinations were chosen and repeated with 
the addition of DEA. No significant signs of separation were observed. 
 
Table 3.11: Effect of ethanol and DEA on the selectivity and resolution of cytarabine 
enantiomers using the Chiralpak AD-H column at three different flow rates. Data 
values ± standard deviation. 
 
MOBILE PHASE 
HEXANE:EtOH:DEA 
(v/v/v) 
 
FLOW RATE 
(ml/min) 
RETENTION 
TIME 
(min) 
MEAN PEAK AREA 
n = 3 
80:20:0.2 
0.5 13.42 7882 ± 271.62 
1 6.62 5072 ± 162.11 
1.5 4.38 3451 ± 57.27 
70:30:0.2 
0.5 8.63 7980 ± 117.68 
1 4.30 4152 ± 51.78 
1.5 2.90 2742 ± 36.86 
60:40:0.2 
0.5 3.62 4295 ± 49.18 
1 2.97 3582 ± 32.00 
1.5 2.37 3042 ± 25.68 
50:50:0.2 
0.5 6.62 7183 ± 85.24 
1 3.35 4285 ± 43.80 
1.5 2.75 3681 ±29.11 
40:60:0.2 
0.5 6.42 8591 ± 65.91 
1 3.27 4354 ± 39.35 
1.5 2.18 3061 ± 27.03 
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3.6 HPLC method for the selectivity and resolution of cytarabine enantiomers on the 
Chiralcel OJ-H and Chiralpak AD-H using acetonitrile: 2-propanol: diethylamine and 
acetonitrile: ethanol: diethylamine 
 
The Chiralcel OD-H, Chiralcel OJ-H and Chiralpak AD-H columns were used with 
different ratios of 2-propanol and ethanol as organic modifiers in acetonitrile together 
with DEA. The selectivity of these three columns as well as the effect of mobile phase 
characteristics on retention and resolution of cytarabine enantiomers was 
investigated.  
Chromatographic conditions - Chromatographic separation of cytarabine enantiomers 
was carried out using an isocratic system at ambient temperature.  Varying 
combinations of acetonitrile: 2-propanol: DEA (v/v/v) and acetonitrile: ethanol: DEA 
(v/v/v) ranging from (95:5:0.2) to (85:15:0.2) was used as mobile phase with flow rates 
of 0.5, 1.0 and 1.5 ml/min. Cytarabine at a concentration of 10 mg % in                          
2-propanol: ethanol (1:1). The injection volume was kept constant at 20 µl and 
cytarabine was analysed at a wavelength of 254 nm. 
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3.6.1 HPLC results for the Chiralcel OD-H using acetonitrile: 2-propanol: DEA (v/v/v) 
 
Attempted separation of enantiomers of cytarabine using flow rates of 0.5, 1.0 and  
1.5 ml/min on the Chiralcel OD-H column. A significant decrease in the retention time 
of cytarabine was observed with increasing concentrations of 2-propanol. 
 
Table 3.12: Effect of 2-propanol on the selectivity and resolution of cytarabine 
enantiomers using the Chiralcel OD-H column at three different flow rates.  Data 
values ± standard deviation. 
 
MOBILE PHASE 
ACN:IPA:DEA 
(v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA  
n = 3 
95:5:0.2 
0.5 14.28 16130± 603.98 
1 6.97 8445 ±169.34 
1.5 5.12 4807 ± 205.34 
90:10:0.2 
0.5 9.87 11609 ±898.46 
1 5.53 5664 ± 165.41 
1.5 3.39 3345 ± 99.49 
85:15:0.2 
0.5 8.58 10364 ± 385.57 
1 4.22 3049 ± 61.90 
1.5 2.64 2513 ± 62.71 
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3.6.2 HPLC results for the Chiralcel OD-H using acetonitrile: ethanol: DEA (v/v/v) 
 
Attempted separation of enantiomers of cytarabine using flow rates of 0.5, 1.0 and 1.5 
ml/min on the Chiralcel OJ-H column. A significant decrease in the retention time of 
cytarabine was observed with increasing concentrations of ethanol. 
 
Table 3.13:  Effect of ethanol on the selectivity and resolution of cytarabine 
enantiomers using the Chiralpak OD-H column at three different flow rates. Data 
values ± standard deviation. 
 
MOBILE PHASE 
ACN:EtOH:DEA 
(v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
85:15:0.2 
0.5 6.00 12758 ± 656.21 
1 3.43 4882 ± 44.74 
1.5 2.57 1924 ± 58.26 
90:10:0.2 
0.5 9.23 12309 ± 479.99 
1 3.20 1708 ± 169.49 
1.5 2.21 831 ± 72.75 
95:5:0.2 
0.5 11.95 11744 ±503.23 
1 6.75 7656 ± 349.38 
1.5 5.87 3644 ±72.06 
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3.6.3 HPLC results for the Chiralcel OJ-H using acetonitrile: 2-propanol: DEA (v/v/v) 
 
Attempted separation of cytarabine enantiomers using flow rates of 0.5, 1.0 and 1.5 
ml/min on the Chiralcel OJ-H column.  
 
Table 3.14: Effect of 2-propanol on the selectivity and resolution of cytarabine 
enantiomers using the Chiralpak OJ-H column at three different flow rates. Data values 
± standard deviation. 
 
MOBILE PHASE 
ACN:IPA:DEA 
(v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
95:5:0.2 
0.5 7.47 12042 ±  136.65 
1 3.50 7168 ±  216.13 
1.5 2.40 4505 ± 71.17 
90:10:0.2 
0.5 
7.13 1209 ± 154.88 
7.93 3680 ± 228.46 
1 3.73 2558 ± 70.85 
1.5 3.15 2511 ± 165.16 
85:15:0.2 
0.5 5.85 11314 ± 876.77 
1 3.80 6054 ± 105.25 
1.5 2.58 3438 ± 131.23 
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3.6.4 HPLC results for the Chiralcel OJ-H using acetonitrile: ethanol: DEA (v/v/v) 
 
Attempted separation of enantiomers of cytarabine using flow rates of 0.5, 1.0 and   
1.5 ml/min on the Chiralcel OJ-H column. A significant decrease in the retention time 
of cytarabine was observed with increasing concentrations of ethanol. 
 
Table 3.15: Effect of ethanol on the selectivity and resolution of cytarabine 
enantiomers using the Chiralpak OJ-H column at three different flow rates. Data values 
± standard deviation. 
 
MOBILE PHASE 
ACN:EtOH:DEA 
(v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME 
(min) 
MEAN PEAK AREA 
n = 3 
95:5:0.2 
0.5 9.87 14504 ± 695.41 
1 4.42 7005 ± 81.42 
1.5 2.95 6037 ± 91.33 
90:10:0.2 
0.5 9.82 9728 ± 67.58 
1 4.33 5748 ± 106.36 
1.5 2.91 4101 ± 77.41 
85:15:0.2 
0.5 8.30 8471 ± 245.40 
1 3.92 5107 ± 54.29 
1.5 2.55 3488 ± 144.72 
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3.6.5 HPLC results for the Chiralpak AD-H using acetonitrile: 2-propanol: DEA (v/v/v) 
 
Attempted separation of enantiomers of cytarabine using flow rates of 0.5, 1.0 and  
1.5 ml/min on the Chiralpak AD-H column. A significant decrease in the retention time 
of cytarabine was observed with increasing concentration of 2-propanol. 
 
Table 3.16: Effect of 2-propanol on the selectivity and resolution of cytarabine 
enantiomers using the Chiralpak AD-H column at three different flow rates. Data 
values ± standard deviation. 
 
MOBILE PHASE 
ACN:IPA:DEA (v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME    
(min) 
MEAN PEAK AREA                  
n = 3 
95:5:0.2 
0.5 13.87 668 ± 229.08 
1 6.70 3716 ± 100.14 
1.5 4.48 2600 ± 71.67 
90:10:0.2 
0.5 11.73 6922 ± 31.13 
1 5.80 3906 ± 70.25 
1.5 3.78 2607 ± 52.72 
85:15:0.2 
0.5 10.63 5594 ±204.02 
1 5.17 3978 ± 119.66 
1.5 3.43 2738 ± 44.30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
3.6.6 HPLC results for the Chiralpak AD-H using acetonitrile: ethanol: DEA (v/v/v) 
 
Attempted separation of enantiomers of cytarabine using flow rates of 0.5, 1.0 and   
1.5 ml/min on the Chiralpak AD-H column. A significant decrease in the retention time 
of cytarabine was observed, with increasing concentrations of ethanol. 
 
Table 3.17: Effect of ethanol on the selectivity and resolution of cytarabine 
enantiomers on the Chiralpak AD-H column at three different flow rates. Data values ± 
standard deviation. 
 
MOBILE PHASE 
ACN:EtOH:DEA 
(v/v/v) 
FLOW RATE 
(ml/min) 
RETENTION TIME    
(min) 
MEAN PEAK AREA                  
n = 3 
95:5:0.2 
0.5 14.47 2262 ± 83.14 
1 7.02 3601 ± 167.31 
1.5 2.18 2949 ± 171.79 
90:10:0.2 
0.5 10.23 6976 ± 36.95 
1 4.98 4510 ± 69.26 
1.5 3.30 2787 ± 40.92 
85:15:0.2 
0.5 8.33 7970 ± 110.61 
1 4.22 4872 ± 123.43 
1.5 2.77 3188 ± 65.57 
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3.7 Gradient elution using the HPLC results for the Chiralpak AD-H column 
Gradient HPLC analysis was performed using the Chiralpak AD-H column. The varying 
mobile phase ratios used, consisted of 2-propanol and ethanol as organic modifiers in 
hexane (Section 2.4.2). Cytarabine was analysed at 254 nm at room temperature. 
 
Chromatographic conditions - The chromatographic separation of cytarabine 
enantiomers was carried out using a gradient system. Throughout the 
chromatographic separation a constant flow rate of 1 ml/min was maintained (unless 
otherwise specified). The injection volume was kept constant at 20 µl. After each run 
the column was allowed to equilibrate prior to the start of the next injection. 
Cytarabine of concentration 10 mg % was made up in 2-propanol: ethanol (1:1). 
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3.7.1 HPLC results for gradient system using hexane: 2-propanol (v/v) with a run time 
of 30 min 
 
The gradient elution was carried out using 2-propanol as an organic modifier in hexane 
(Section 2.4.2 Fig 2.5) in 30 min at a flow rate of 1 ml/min. 
Table 3.18: Effect of gradient elution using varying combinations of hexane:                  
2-propanol on selectivity and resolution of cytarabine enantiomers. Data values ± 
standard deviation. 
 
MOBILE PHASE  
Hexane: IPA (v/v) 
RETENTION TIME 
 (min) 
MEAN PEAK AREA 
n = 2 
95:5 - 90:10 24.10 4441 ± 81.12 
 
3.7.2 HPLC results for the gradient system using hexane: 2-propanol (v/v) at flow 
rate 1.0 ml/min run time 22 min 
 
The gradient elution was carried out using 2-propanol as an organic modifier in hexane 
(Section 2.4.2 Fig 2.7, Fig 2.8, Fig 2.9, Fig 2.10, Fig 2.11, Fig 2.12, and Fig 2.13). A 
significant decrease in the retention times of cytarabine was observed with increasing 
concentrations of the organic modifier. Mobile phase ratio of ranging from hexane: 2-
propanol (70:30 - 65:35) showed partial separation. 
Table 3.19: Effect of gradient elution using varying combinations of                       
hexane: 2-propanol on selectivity and resolution of cytarabine enantiomers. Data 
values ± standard deviation. 
 
MOBILE PHASE  
Hexane: IPA (v/v) 
RETENTION TIME 
 (min) 
MEAN PEAK AREA 
n = 2 
90:10 - 85:15 12.03 7133 ± 58.68 
85:15 - 80:20 6.93 6566 ± 22.12 
90:10 - 85:15 5.30 6686 ± 6.56 
75:25 - 70:30 4.17 6158 ± 14.59 
70:30 - 65:35 
3.45 1612 ± 16.82 
3.88 4774 ± 10.52 
65:35 - 60:40 3.62 5523 ± 57.05 
60:40 - 55:45 3.50 6416 ± 16.24 
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3.7.3 HPLC results for gradient system using hexane: 2-propanol (v/v) at flow rate – 
0.5 ml/min in 22 min 
 
From the attempted conditions given in Table 19, ratio consisting of 30 %-35 % of         
2-propanol in hexane was chosen and repeated with a flow rate of 0.5 ml/min (Section 
2.4.2, Fig 2.11). 
Table 3.20: Effect of gradient elution using varying combinations of hexane: 2-
propanol on selectivity and resolution of cytarabine enantiomers. Data values ± 
standard deviation. 
 
MOBILE PHASE 
Hexane: IPA (v/v) 
RETENTION TIME  
(min) 
MEAN PEAK AREA 
n = 2 
70:30 - 65:35 
7.45 3529 ± 1427.94 
8.08 6112 ± 1287.47 
  
3.7.4 HPLC results for gradient system using hexane: ethanol (v/v) flow rate – 1.0 
ml/min in 22 min 
 
The gradient elution was carried out using ethanol as an organic modifier in hexane 
(Section 2.4.2, Fig 2.7, Fig 2.8, Fig 2.9, Fig 2.10, Fig 2.11, Fig 2.12, and Fig 2.13). A 
significant decrease in the retention times of cytarabine was observed with the 
increasing concentrations of the organic modifier.  
Table 3.21: Effect of gradient elution using varying combinations of hexane: ethanol 
on selectivity and resolution of cytarabine enantiomers. Data values ± standard 
deviation. 
 
MOBILE PHASE  
Hexane: EtOH (v/v) 
RETENTION TIME 
 (min) 
MEAN PEAK AREA 
n = 2 
90:10 - 85:15 14.08 5895 ± 8.02 
85:15- 80:20 9.28 6248 ± 43.91 
70:30 - 65:35 5.02 6538± 50.74 
65:35 - 40:40 3.90 5257 ± 60.01 
60:40 - 55:45 3.82 6561 ± 28.51 
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3.7.5 HPLC results for gradient system using hexane: ethanol (v/v) flow rate – 1.0 
ml/min in 40 min 
The gradient elution was carried out using ethanol as an organic modifier in hexane 
(Section 2.4.2, Fig 2.6) in 40 min at a flow rate of 1ml/min. 
Table 3.22: Effect of gradient flow of ethanol (5 % - 10 %) on selectivity and resolution 
of cytarabine enantiomers. Data values ± standard deviation. 
 
MOBILE PHASE  
Hexane: EtOH (v/v)  
RETENTION TIME 
 (min) 
MEAN PEAK AREA 
n = 2 
95:5 - 90:10 30.95 5171 ± 33.89 
 
 
3.7.6 HPLC results for gradient system using hexane: 2-propanol (v/v)  
 
The gradient elution was carried out using 2-propanol 10 % - 35 % as an organic 
modifier in hexane (Section 2.4.2, Fig 2.14) in 17 min at a flow rate of 1ml/min. 
Table 3.23: Effect of gradient flow of 2-propanol (10% - 35%) in hexane on selectivity 
and resolution of cytarabine enantiomers. Data values ± standard deviation. 
 
MOBILE PHASE 
Hexane: IPA (v/v) 
RETENTION TIME  
(min) 
MEAN PEAK AREA 
n = 2 
90:10 - 65:35 8.30 6526 ± 47.68 
 
 
3.7.7 HPLC results for gradient system using hexane: ethanol (v/v)  
 
The gradient elution was carried out using ethanol 10 % - 35 % as an organic modifier 
in hexane (Section 2.4.2, Fig 2.14) in 17 min at a flow rate of 1ml/min. 
Table 3.24: Effect of gradient flow of ethanol (10 % - 35 %) in hexane on selectivity and 
resolution of cytarabine enantiomers. Data values ± standard deviation. 
 
MOBILE PHASE  
Hexane: EtOH (v/v)  
RETENTION TIME 
 (min) 
MEAN PEAK AREA 
n = 2 
90:10 - 65:35 9.82 6264 ± 33.69 
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4. DISCUSSION 
 
Chiral molecules are at the forefront of strategies for more effective and safe drugs. 
The number of chiral pharmaceutical drugs in need of separation has been increasing 
steadily during recent years (De la Puente, 2004). The characteristic features which 
interests researchers in exploring chiral drugs is their ability to differ in their 
pharmacology and toxicology (Wang et al., 2003). Chiral chromatography is an 
important analytical technique used for the separation of enantiomers that could be 
inactive or harmful (Nageswara et al., 2006a). The separation of enantiomers requires 
a chiral or asymmetric environment that allows diastereomeric interactions, hence, 
HPLC is widely applied (Torok et al., 2005). In general practice chiral method 
development is usually accomplished via a trial and error approach, sometimes 
defined as a process of elimination (Blackwell et al., 1999). This study was an attempt 
to separate the enantiomers of cytarabine (Ara-C or 1-β-D-arabinofuranosylcytosine) 
using a polysaccharide based chiral stationary phase (CSP). Cytarabine is a well known 
nucleoside analogue used in chemotherapy for the treatment of acute lymphoblastic 
and myelogenous leukaemia (Foulon et al., 2009). The various factors identified in the 
literature affecting chiral resolution are the nature of chiral compound and chiral 
selectors, the mobile phase composition and condition, column efficiency and 
temperature (Peng et al., 2010). The effect of these factors on enantiomer recognition 
for cytarabine on three different columns namely, Chiralcel OD-H, Chiralcel OJ-H and 
Chiralpak AD-H were studied. Parameters such as the type of column, concentration of 
organic modifier (2-propanol or ethanol), effect of DEA, effect of acetonitrile in 
combination with the organic modifiers using normal isocratic elution and the effect of 
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gradient elution on Chiralpak AD-H on resolution of cytarabine enantiomers are 
discussed below.  
 
4.1 Mechanism of Chiralcel OD-H, Chiralcel OJ-H and Chiralpak AD-H columns: 
Polysaccharide based chiral stationary phases developed by Okamoto and co-workers 
were used since they showed the broadest applicability to date                                       
(Persson and Andersson, 2001). Three different polysaccharide based stationary 
phases were evaluated: Chiralcel OD-H cellulose tris (3, 5-dimethylphenylcarbamate), 
Chiralcel OJ-H cellulose tris (4-methylbenzoate) and Chiralpak AD-H amylose tris               
(3, 5-dimethylphenylcarbamate). The chiral recognition mechanism of these CSP’s is 
due to the formation of solute chiral stationary phase complexes through inclusion of 
enantiomers into the chiral cavities in higher order structures of the CSP’s. The 
carbamate structural unit has been found to be the most important adsorbing site on 
the phenylcarbamate derivatives of polysaccharides (Chiralcel OD-H and Chiralpak AD-
H) which are used in chiral recognition. In carbamate derivative CSP’s the binding of 
the solutes to the CSP’s is through interaction between the solutes and the polar 
carbamate groups on the CSP’s (Nageswara et al., 2006b). On one hand there are 
interactions through hydrogen bonding between the carbonyl group of the carbamate 
and the OH and NH groups of the solute. There are also interactions of the same type 
between the NH groups of the carbamate unit and the carbonyl groups of solute and 
through π-π interaction between solutes and phenyl groups of CSP                            
(Kunath et al., 1996). The cellulose derivative has been reported to exist in a 
conformation of a left-handed threefold (3/2) helix, while the amylose derivative can 
be regarded as a left-handed fourfold (4/1) helix. Also the amylase derivative is more 
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helical in nature and has well defined cavities compared to cellulose analogues                                         
(Aboul-Enein and Ali et al., 2001). Therefore the resolving ability of amylose and 
cellulose derivatives with the same (3, 5-dimethylphenylcarbamate) moiety are very 
different (Nageswara et al., 2006a). In both chiral biopolymers a helical groove exists 
with polar carbamate residues and 3, 5-dimethylphenyl groups, the enantiomers enter 
the groove and interact as described with CSP’s (Kunath et al., 1996).  
It is generally thought that the chiral recognition mechanism of                                                 
tris (4-methylbenzoate) of cellulose is similar to the other two polysaccharide 
derivatives  of CSP’s, based on the formation of transient enantiomer-CSP complexes 
through the insertion of enantiomer in the chiral cavities of the selector. The basic 
material of these phases consists of cellulose tris (4-methylbenzoate).  Cellulose is a 
linear polysaccharide containing 1500 (+) glucose units per molecule, which are 
arranged in parallel bundles in cellulose fibres and are held together by numerous 
hydrogen bonds between various hydroxyl groups. Their helical structure makes it 
possible to interact stereospecifically with enantiomers. The main chiral adsorption 
site on the OJ-H column seems to be associated with polar carbonyl groups that are 
located along the polymer backbone and are capable of interacting with analyte via 
acceptor hydrogen bonding and dipole-dipole interactions.  The aromatic groups that 
are positioned outside the polymer chain also provide sites for π-π and steric 
interaction with analytes (Cirilli et al., 2009). These interactions are relatively weak and 
are considered more effective under normal-phase conditions                                     
(Tachibana and Ohnishi et al., 2001). These differences in the chiral recognition 
mechanism could be attributed to different configurations of the glucose residues            
(α and β linkages) and higher order structure of chiral stationary phase                         
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(Nageswara et al., 2006b). Based on the chiral recognition model proposed for the 
Chiralcel OD-H and Chiralpak AD-H columns, it is assumed that the cytarabine 
enantiomers interact with the CSP’s via (1) hydrogen bonding between the nitrogen 
atoms of cytarabine molecules and the amide proton of the carbamate moiety of the 
CSP’s; (2) charge transfer (π-π) interactions between the pyridine moiety of cytarabine 
and the phenyl groups of the CSP’s and (3) dipole-dipole interaction between the 
nitrogen atoms of the cytarabine and the carbonyl oxygen of the carbamate moiety of 
the Chiralcel OD-H and Chiralpak AD-H columns. The phenyl moiety can furthermore 
provide π-π interactions with the aromatic group of the compound                             
(Ducret et al., 1998). For Chiralcel OJ-H (1) the hydrogen bonding between the 
nitrogen atoms of cytarabine molecule and the polar ester function via hydrogen 
bonding and dipole-dipole interactions.  (2) Charge transfer (π-π) interactions between 
pyridine moiety of cytarabine and methyl groups of the CSP, however, a detailed 
separational mechanism for chiral solute has not yet been fully established. 
It is well known that the performance of a specific column is affected by the 
composition and the flow rate of the mobile phase (Zhou et al., 2006). Experiments 
were carried out to find the optimal composition and flow rate for resolution of 
cytarabine enantiomers for each column. Two classes of mobile phases were 
attempted using the isocratic mode, normal phase hexane and polar phase 
acetonitrile. 2-propanol and ethanol were tested on both the phases as polar organic 
modifiers at three different flow rates of 0.5 ml/min, 1 ml/min and 1.5 ml/min. The 
most promising results were repeated with the addition of DEA. 
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4.2 Effect of 2-propanol and ethanol content of the mobile phase on Chiralcel OJ-H 
and Chiralpak AD-H upon enantioselectivity of cytarabine: 
 
The effect of 2-propanol on peak characteristics of cytarabine was investigated by 
increasing the concentration of 2-propanol in mixed hexane: 2-propanol phase from 
10 to 60 %, the results indicated partial resolution of cytarabine enantiomers with                
2-propanol as a polar modifier in hexane, on Chiralcel OJ-H and Chiralpak AD-H 
columns shown in Tables 3.3 and Table 3.4 respectively. In comparison to                    
Chiralcel OJ-H, Chiralpak AD-H showed better resolution of cytarabine enantiomers 
using 2-propanol at ratios of 30 % 40 % and 50 %. This could be due to the amylose 
backbone instead of cellulose in Chiralpak AD-H  which exhibits rather high 
enantiomer resolving ability as compared to its cellulose analog                          
(Chankvetadze et al., 2002). Comparatively, the separation was better at higher flow 
rates (1.5 ml/min) with the Chiralpak AD-column.  
The effect of ethanol on peak characteristics of cytarabine was investigated by 
increasing the concentration of ethanol in hexane: ethanol combinations from 10 to  
60 %. The results showed partial separation on Chiralcel OJ-H and Chiralpak AD-H 
columns shown in Table 3.6 and Table 3.7, respectively. Ethanol compared with 2-
propanol, did not yield encouraging results, infact the broad nature of the peaks 
resulted in a loss in resolution.  A combination of 60% hexane and 40% ethanol was 
found to be the best however, it did not resolve the enantiomers completely.  
The retention and resolution of cytarabine enantiomers using 2-propanol in hexane 
differed from that of ethanol in hexane on the Chiralcel OJ-H and Chiralpak AD-H 
columns, the main reason for the differing separation property of the 2-propanol and 
ethanol may be due to a changed geometry and /or size of the chiral grooves of the 
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CSP’s which is caused by the type of alcohol modifier used (Tatini et al., 2005).  In this 
investigation it was also found that in the results showing partial resolution the peak 
shape varied with the use of two different modifiers, which could possibly be due to 
the steric hindrance of the alcohol content in the mobile phase. In the results 
indicating partial resolution, the possible change in the peak shape could be due to  
the change of the order of elution which can be associated with the use of different 
modifiers (2-propanol or ethanol) which may have caused alteration to the steric 
environment of the chiral cavities in the CSP’s (Wang et al., 2003). 
 
4.3 Effect of 2-propanol and ethanol content of the mobile phase on Chiralcel OD-H 
for resolution of cytarabine enantiomers: 
 
The type and concentration of organic modifiers was found to influence the resolution 
and retention of cytarabine. The HPLC results for Chiralcel OD-H using 2-propanol 
Table 3.2 and ethanol Table 3.5 as organic modifiers in hexane clearly showed no signs 
of resolution of cytarabine enantiomers. A comparison of the results for the two 
organic modifiers indicated that ethanol provided improved selectivity for cytarabine 
while the retention time was less compared to 2-propanol. In the cavity of CSP’s the 
lower alcohols could be inserted easily as compared to longer chain alcohols 
(Nageswara et al., 2006b). This phenomenon could have been attributed to the steric 
effects around the hydroxyl moiety of the 2-propanol and ethanol. The insertion of the 
polar mobile phase modifier into the cavities of CSP’s could induce changes in the 
main chiral recognition mechanisms, leading to the formation of more stable 
diastereomeric complexes of enantiomers causing higher retention and better 
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selectivity. However, no further combinations of mobile phases were tried on Chiralcel 
OD-H due to time limitation. 
 
4.4 Effect of concentration of alcohol modifier (2-propanol or ethanol) upon 
enantioselectivity of cytarabine:  
 
The retention of the analyte is highly influenced by the amount of polar modifier in 
apolar mobile phases (Persson and Andersson, 2001). It was                                                                                                                                                                  
noted that the decrease in the polar component of the mobile phase resulted in 
reduction in the retention time of cytarabine. This phenomenon was observed in all 
three columns used, the decrease in retention time was due to the increased polarity 
of the MP with an increasing alcohol concentration (Torok et al., 2005). Since the 
solvent molecules compete with the solute molecules for the specific adsorption sites 
on the CSP, however, the solvation of the mobile phase increases with the increased 
modifier content.  
 
4.5 Effect of diethylamine (DEA) as a residual silinol deactivator upon 
enantioselectivity of cytarabine using Chiralcel OJ-H and Chiralpak AD-H columns:  
 
The influence of DEA on enantioseparation of cytarabine was assessed on Chiralcel 
OJ-H and Chiralpak AD-H columns  by using 0.2 % in various mobile phases which had 
showed partial resolution consisting of mixtures of hexane: 2-propanol and                
hexane: ethanol (Table 3.8, Table 3.9, Table 3.10, and Table 3.11). It is known that 
basic mobile phase additives could be used in chiral separations to increase 
enantioselectivity, it minimizes peak broadening arising from the unwanted 
interactions between polar solutes and the stationary phase (Matthijs et al., 2006). 
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DEA was used to reduce peak tailing by masking the residual silanol of the CSP’s 
(Sharma et al., 1995). With the type of columns used, consisting of a free silanol 
groups on the silica surface, results in secondary interactions with the nitrogen atoms 
of cytarabine, leading to improved peak symmetry. DEA effectively masks the 
underivatized silanols, thus minimizing the adsorption effect and the resultant peak 
tailing (Tatini et al., 2005).  Although the use of DEA resulted in greater peak symmetry 
there was no apparent improvement observed in the retention or enantioselectivity of 
the cytarabine enantiomers. However, a ratio of hexane: ethanol: DEA (60:40:0.2) 
using OJ-H column showed some enantioselectivity compared to the other 
combinations. 
 
4.6 Effect of Acetonitrile upon enantioselectivity of cytarabine: 
 
The results of the effect of varying ratios of the organic modifier 2-propanol in 
acetonitrile together with DEA for Chiralcel OD-H, Chiralcel OJ-H and Chiralpak AD-H 
are mentioned in Table 3.12, Table 3.14 and Table 3.16, respectively. The varying 
compositions of ethanol in acetonitrile together with DEA had little or no effect on 
enantioselectivity of cytarabine shown in Table 3.13, Table 3.15 and Table 3.17 
respectively. With the OD-H column the varying ratios of 2-propanol with acetonitrile 
provided higher retention times compared with ethanol. With the OJ-H column the 
ratios with 2-propanol resulted in the lowest retention time. With the AD-H column 
the varying ratios of 2-propanol as organic modifier resulted in a higher retention time 
compared to ethanol. Neither of these ratios proved to be useful in separating the 
enantiomers of cytarabine which could possibly be since the solvents (acetonitrile, 
ethanol and 2-propanol) used were polar.  
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4.7 Effect of gradient elution upon enantioselectivity of cytarabine on Chiralpak           
AD-H 
 
A gradient elution of the cytarabine was carried out in order to see whether the 
enantiomers could be separated without having to make up various mobile phases and 
to see whether gradually changing the mobile phase composition to a more polar 
system would prove useful in separating the enantiomers. The gradient systems 
resulting in partial resolution are listed in Tables 3.19 and 3.20. However, the gradient 
method proved not to be as effective as the isocratic system. Increasing the polarity of 
the mobile phase decreased the retention time of the cytarabine as expected            
(Torok et al., 2005). The gradient elution was not explored on other two columns due 
to time limitation. 
4.8 Limitations 
 
1. There was considerable variation in the peak shape even after repeated injections of 
the cytarabine under the same conditions and was most likely attributed to the non-
buffering mobile phase. It is worth noting that the presence of an aqueous 
environment would be detrimental to the integrity of the columns used. 
2. Even with the analysis carried out using Chiralpak AD-H column at temperatures 
higher that the room temperature (30, 35 and 40) no significant improvement in 
resolving the peaks was achieved. 
3. Due to time constraints gradient elution could not be explored using the Chiralcel 
OD-H and Chiralcel OJ-H columns. 
4. The alcohol content (2-propanol or ethanol) more than 70 % in hexane was found 
unfavourable to the integrity of the HPLC system at flow rates of 0.5, 1.0 and 1.5 
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ml/min and hence could not be tested on Chiralcel OD-H, Chiralcel OJ-H and Chiralpak 
AD-H. 
 
4.9 CONCLUSION 
 
Separation of cytarabine enantiomers was attempted on three different 
polysaccharide-based chiral stationary phases namely the Chiralcel OD-H, Chiralcel OJ-
H and Chiralpak AD-H column.  The conditions that afforded the best separation 
involved the use of the Chiralcel OJ-H column using varying compositions of hexane, 
ethanol and diethylamine and use of the Chiralpak AD-H column using mobile phase 
ratios consisting of hexane: 2-propanol and hexane: 2-propanol: diethylamine. The 
application of the Chiralcel OD-H column with varying compositions proved to be less 
effective to separate cytarabine enantiomers. The application of gradient elution did 
not help much to resolve the enantiomers. It can be concluded that the Chiralcel OJ-H 
and Chiralpak AD-H columns can only give partial resolution using 2-propanol and 
ethanol as organic modifiers, while DEA did not help improve the resolving power, 
however it did reduce tailing. Using various combinations of organic modifiers            
(2-propanol or ethanol) in acetonitrile with the addition of DEA could not enhance 
separation. In conclusion, the aim of developing a chiral HPLC method in order to 
separate specific enantiomers of anticancer reagent cytarabine using chiral HPLC 
under specified conditions proved to be unsuccessful. Therefore the isolation and 
purification of individual enantiomers by semi-preparative HPLC could not be 
performed since the results varied considerably even after repeated injections under 
the same conditions which could have been attributed to non-buffering mobile 
phases. 
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4.10 SCOPE FOR FUTURE WORK 
 
1. Although partial resolution of cytarabine enantiomers was achieved using ethanol 
and 2-propanol as organic modifier in hexane, the use of solvents such as 
methanol, 1-butanol,  tert-butanol,  1-propanol, 1-pentanol and 1-hexanol could be 
investigated as organic modifiers to check their effect on enantioselectivity of 
cytarabine. 
2. Further work could be carried out using varying column temperatures using the 
Chiralcel OD-H and Chiralcel OJ-H columns, to investigate their effect on 
enantioseparation of cytarabine.  
3. Enantiomeric separations of cytarabine could be investigated by HPLC using 
macrocyclic glycopeptide-based chiral stationary phases. 
4. Chiralpak AS-H column, that has a packing composition of amylose tris                       
(S)-α-methylbenzylcarbamate can be investigated for its effect on separation of 
cytarabine enantiomers. 
5. Reversed-phase liquid chromatographic separations can be investigated on 
polysaccharide based chiral stationary phases such as Chiralpak® AS-RH, Chiralpak® 
AD-RH, Chiralcel® OD-RH ,Chiralcel® OJ-RH, Chiral AGP column based on α1-acid 
glycoprotein (α1-AGP) and Chiral CBH based on Cellobiohydrolase (CBH) . 
6. Due to time constraints the gradient elution of the Chiralcel OD-H, Chiralcel OJ-H 
columns was not carried out and therefore could be investigated. 
7. Ligand-exchange based chiral stationary phase such as Chiralpak WH, Chiralpak 
WM and Chiralpak WE could be investigated. 
8. Protein based chiral stationary phases such as Chiral AGP could be investigated for 
their effect on enantioseparation of cytarabine.  
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6. APPENDIX 
Appendix 1 
 
A. 
 
              
 
B. 
 
Figure 6.1: HPLC chromatogram showing results for cytarabine using 50% hexane and 
50% ethanol (A) at  flow rate 0.5 ml/min on the Chiralcel OD-H column and (B) at  flow 
rate 1.0 ml/min on the Chiralcel OD-H column. 
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Figure 6.2: HPLC chromatogram showing results for cytarabine using 50% hexane and 
50% ethanol at flow rate 1.5 ml/min on the Chiralcel OD-H column. 
 
 
 
Appendix 2: HPLC Results for cytarabine using gradient elution on a Chiralpak AD-H 
column. 
 
A. 
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B. 
 
 
Figure 6.3: HPLC chromatogram showing results for cytarabine using gradient system 
with 2-propanol ranging from 30 to 35% in hexane in 22min (A) at flow rate 0.5 ml/min 
on the Chiralpak AD-H column and (B) at flow rate 1.0 ml/min on the Chiralpak AD-H 
column. 
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Appendix 3: 
Calculation of specific rotation of sucrose: 
 
                                    
 
    
  = 
                                
                                               
 
 
 
 
     
  
                      = 3.2906   
0.050010 x 1 
                                                                       
                                                                         =         (+) 65.79 
 
Calculation of specific rotation of cytarabine: 
 
     
  
                      = 1.5584   
0.01014 x 1 
                                                                       
                                                                         =         (+) 153.68 
 
